Date,Articles
2007-01-05,"{""abstract"": ""Merck of Germany said Friday that it is considering the sale of its generic drugs business, which could fetch more than $5 billion, according to some estimates. Reuters reported that the German drugs and chemicals group seems eager to cut debt from its recent $13.3 billion acquisition of Serono, which it is financing largely through loans. "", ""web_url"": ""https://dealbook.nytimes.com/2007/01/05/germanys-merck-may-sell-generic-drugs-unit/"", ""snippet"": """", ""lead_paragraph"": ""Merck of Germany said Friday that it is considering the sale of its generic drugs business, which could fetch more than $5 billion, according to some estimates. Reuters reported that the German drugs and chemicals group seems eager to cut debt from its recent $13.3 billion acquisition of Serono, which it is financing largely through loans. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Germany\u2019s Merck May Sell Generic Drugs Unit"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-01-05T13:32:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1e983f50-46dc-5210-afa5-fdcbd7a86532"", ""word_count"": 127, ""uri"": ""nyt://article/1e983f50-46dc-5210-afa5-fdcbd7a86532""}"
2007-01-12,"{""abstract"": ""The German drugmaker Merck KGaA has attracted interest in its generic drugs unit from Cinven, Permira and the Texas Pacific Group, people familiar with the matter told Reuters. Merck \u2014 no relation to the United States company of the same name \u2014 said last week it was considering selling the business, valued at more than 4 billion euros ($5.2 billion), as it retrains its focus on higher-revenue branded products. Merck declined to comment, as did Permira and Cinven, while Texas Pacific was not available to comment, Reuters said."", ""web_url"": ""https://dealbook.nytimes.com/2007/01/12/private-equity-shows-interest-in-mercks-generics-unit/"", ""snippet"": """", ""lead_paragraph"": ""The German drugmaker Merck KGaA has attracted interest in its generic drugs unit from Cinven, Permira and the Texas Pacific Group, people familiar with the matter told Reuters. Merck \u2014 no relation to the United States company of the same name \u2014 said last week it was considering selling the business, valued at more than 4 billion euros ($5.2 billion), as it retrains its focus on higher-revenue branded products. Merck declined to comment, as did Permira and Cinven, while Texas Pacific was not available to comment, Reuters said."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Unit of Germany\u2019s Merck Said to Attract Buyout Firms"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-01-12T13:38:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/70b4364e-43c7-5af9-b234-e6f07ce3b288"", ""word_count"": 92, ""uri"": ""nyt://article/70b4364e-43c7-5af9-b234-e6f07ce3b288""}"
2007-01-18,"{""abstract"": ""A lawsuit against Merck sought medical monitoring for former users of the painkiller Vioxx."", ""web_url"": ""https://www.nytimes.com/2007/01/18/business/19vioxx.html"", ""snippet"": ""A lawsuit against Merck sought medical monitoring for former users of the painkiller Vioxx."", ""lead_paragraph"": ""A lawsuit against Merck that seeks medical monitoring for former users of the painkiller Vioxx was revived yesterday by a New Jersey appeals court."", ""print_section"": ""C"", ""print_page"": ""18"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""New Jersey Court Revives a Merck Suit"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""New Jersey Court Revives a Merck Suit"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""New Jersey"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Decisions and Verdicts"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-01-18T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/69e4167c-62d9-5708-a556-26b544554aa2"", ""word_count"": 124, ""uri"": ""nyt://article/69e4167c-62d9-5708-a556-26b544554aa2""}"
2007-02-15,"{""abstract"": ""Merck & Company agreed Wednesday to pay $2.3 billion to resolve several tax disputes, the Internal Revenue Service said. The drug company\u2019s payment includes taxes, interest and penalties stemming from the disputes, which cover the tax years 1993-2001 and arose in part from Merck\u2019s use of minority equity interest financing, the I.R.S. said."", ""web_url"": ""https://dealbook.nytimes.com/2007/02/15/merck-to-pay-23-billion-to-the-irs/"", ""snippet"": """", ""lead_paragraph"": ""Merck & Company agreed Wednesday to pay $2.3 billion to resolve several tax disputes, the Internal Revenue Service said. The drug company\u2019s payment includes taxes, interest and penalties stemming from the disputes, which cover the tax years 1993-2001 and arose in part from Merck\u2019s use of minority equity interest financing, the I.R.S. said."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck to Pay $2.3 Billion to the I.R.S."", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-02-15T12:31:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/df1a11b9-6448-52af-a7a6-386eadfab18e"", ""word_count"": 64, ""uri"": ""nyt://article/df1a11b9-6448-52af-a7a6-386eadfab18e""}"
2007-02-17,"{""abstract"": ""At about $400 the vaccine is costly, and many say the rush toward mandatory inoculation could prove counterproductive."", ""web_url"": ""https://www.nytimes.com/2007/02/17/health/17vaccine.html"", ""snippet"": ""At about $400 the vaccine is costly, and many say the rush toward mandatory inoculation could prove counterproductive."", ""lead_paragraph"": ""Racing to embrace a new vaccine, at least 20 states are considering mandatory inoculation of young girls against the sexually transmitted virus that causes cervical cancer."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/02/17/business/17vacc600.1.jpg"", ""height"": 300, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2007/02/17/business/17vacc600.1.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 300}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/02/17/business/17vacc75.1.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/02/17/business/17vacc75.1.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Furor on Rush to Require Cervical Cancer Vaccine"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Furor on Rush to Require Cervical Cancer Vaccine"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Human Papilloma Virus (HPV)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-02-17T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Stephanie Saul and Andrew Pollack"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4469e224-ab13-5d27-8bec-46e65d5340ea"", ""word_count"": 1775, ""uri"": ""nyt://article/4469e224-ab13-5d27-8bec-46e65d5340ea""}"
2007-02-21,"{""abstract"": ""Public reaction forced the drug manufacturer to ends its lobbying efforts in state legislatures on behalf of a cervical cancer vaccine."", ""web_url"": ""https://www.nytimes.com/2007/02/21/business/21merck.html"", ""snippet"": ""Public reaction forced the drug manufacturer to ends its lobbying efforts in state legislatures on behalf of a cervical cancer vaccine."", ""lead_paragraph"": ""Reacting to a furor from some parents, advocacy groups and public health experts, Merck said yesterday that it would stop lobbying state legislatures to require the use of its new cervical cancer vaccine. "", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck to Halt Lobbying for Vaccine for Girls"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Lobbying For Vaccine To Be Halted"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Human Papilloma Virus (HPV)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lobbying and Lobbyists"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2007-02-21T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack and Stephanie Saul"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9abca0f9-2712-5fe1-8868-5cc2cb7cca49"", ""word_count"": 778, ""uri"": ""nyt://article/9abca0f9-2712-5fe1-8868-5cc2cb7cca49""}"
2007-03-03,"{""abstract"": ""A New Jersey jury ruled that Merck failed to provide adequate warning about the risks of its Vioxx painkiller in one of two cases decided."", ""web_url"": ""https://www.nytimes.com/2007/03/03/business/03vioxx.html"", ""snippet"": ""A New Jersey jury ruled that Merck failed to provide adequate warning about the risks of its Vioxx painkiller in one of two cases decided."", ""lead_paragraph"": ""A New Jersey state jury ruled that Merck had failed to provide adequate warning about the risks of its Vioxx painkiller in one of two cases decided yesterday."", ""print_section"": ""C"", ""print_page"": ""8"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Mixed Verdicts for Merck in Vioxx Cases"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Mixed Verdicts for Merck in Vioxx Cases"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""glocations"", ""value"": ""New Jersey"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Decisions and Verdicts"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2007-03-03T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/df076dc7-a994-5803-a627-8d1b3e779ab9"", ""word_count"": 705, ""uri"": ""nyt://article/df076dc7-a994-5803-a627-8d1b3e779ab9""}"
2007-03-08,"{""abstract"": ""Private equity bidders are reportedly lining up to do battle over the generics business of Germany\u2019s Merck, said to be worth at least 4 billion euros ($5.3 billion). The Financial Times Deutschland reported that Bain Capital and Apax Partners are preparing a joint bid for the business, as are Kohlberg Kravis Roberts and Warburg Pincus. The Carlyle Group is also reportedly mulling a bid. "", ""web_url"": ""https://dealbook.nytimes.com/2007/03/08/buyout-shops-prep-bids-for-merck-unit/"", ""snippet"": """", ""lead_paragraph"": ""Private equity bidders are reportedly lining up to do battle over the generics business of Germany\u2019s Merck, said to be worth at least 4 billion euros ($5.3 billion). The Financial Times Deutschland reported that Bain Capital and Apax Partners are preparing a joint bid for the business, as are Kohlberg Kravis Roberts and Warburg Pincus. The Carlyle Group is also reportedly mulling a bid. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Buyout Firms Circle Unit of German Drugmaker Merck"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-03-08T12:29:57+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8630c5b0-6ab0-5afb-a483-ea4c18b625d8"", ""word_count"": 123, ""uri"": ""nyt://article/8630c5b0-6ab0-5afb-a483-ea4c18b625d8""}"
2007-03-29,"{""abstract"": ""Unusual side effects \u2014 including hallucinations and disorientation \u2014 showed up in the studies. The drug also failed a trial of its efficacy."", ""web_url"": ""https://www.nytimes.com/2007/03/29/business/29sleep.html"", ""snippet"": ""Unusual side effects \u2014 including hallucinations and disorientation \u2014 showed up in the studies. The drug also failed a trial of its efficacy."", ""lead_paragraph"": ""Two weeks after the Food and Drug Administration issued safety warnings about widely used sleeping pills, the drug maker Merck canceled a venture into the shifting market for insomnia medications. "", ""print_section"": ""C"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Cancels Work on a New Insomnia Medication"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Cancels Work on a New Insomnia Medication"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tests and Testing"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sleep"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Insomnia"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2007-03-29T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/64349d53-1cee-50af-bb93-788b8d4a0a9d"", ""word_count"": 737, ""uri"": ""nyt://article/64349d53-1cee-50af-bb93-788b8d4a0a9d""}"
2007-04-12,"{""abstract"": ""The F.D.A. rejected Arcoxia because of concerns that the drug could cause as many as 30,000 heart attacks a year if widely used."", ""web_url"": ""https://www.nytimes.com/2007/04/12/business/12cnd-drug.html"", ""snippet"": ""The F.D.A. rejected Arcoxia because of concerns that the drug could cause as many as 30,000 heart attacks a year if widely used."", ""lead_paragraph"": ""GAITHERSBURG, Md., April 12 \u2014 A panel of federal drug advisers voted 20-to-1 today to reject an application by Merck to sell its pain pill Arcoxia because of concerns that the drug could cause as many as 30,000 heart attacks a year if widely used."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""F.D.A. Panel Rejects Merck Pain Pill in 20-1 Vote"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Panel Rejects Merck Pain Pill in 20-1 Vote"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2007-04-12T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""ContinuousNews"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Gardiner Harris"", ""person"": [{""firstname"": ""Gardiner"", ""middlename"": null, ""lastname"": ""Harris"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b2da8f8a-df38-5f27-8ea6-2e149389c8c6"", ""word_count"": 878, ""uri"": ""nyt://article/b2da8f8a-df38-5f27-8ea6-2e149389c8c6""}"
2007-04-16,"{""abstract"": ""EARNINGS REPORTS The following companies are scheduled to release earnings reports this week: Citigroup, Eli Lilly, Mattel and Wachovia (Monday); TD Ameritrade Holding, Comerica, CSX, Dow Jones, EMC, Intel, I.B.M., Johnson & Johnson, Mellon Financial, Northern Trust, Wells Fargo and Yahoo (Tuesday); Abbott Laboratories, Commerce Bancorp, E*Trade Financial, eBay, JPMorgan Chase, Motorola, PNC Financial Services, Allstate, Bank of New York, Tribune and United Technologies (Wednesday); Advanced Micro Devices, Altria Group, Continental Airlines, D. R. Horton, First Data, Gannett, Google, Merck, Merrill Lynch, Nokia, Schering-Plough, Southwest Airlines, UnitedHealth Group and Wyeth (Thursday); Caterpillar, Honeywell, McDonald\u2019s, SAP, Schlumberger and Xerox (Friday)."", ""web_url"": ""https://www.nytimes.com/2007/04/16/business/16ahead.html"", ""snippet"": ""EARNINGS REPORTS The following companies are scheduled to release earnings reports this week: Citigroup, Eli Lilly, Mattel and Wachovia (Monday); TD Ameritrade Holding, Comerica, CSX, Dow Jones, EMC, Intel, I.B.M., Johnson & Johnson, Mellon Financ..."", ""lead_paragraph"": ""EARNINGS REPORTS The following companies are scheduled to release earnings reports this week: Citigroup, Eli Lilly, Mattel and Wachovia (Monday); TD Ameritrade Holding, Comerica, CSX, Dow Jones, EMC, Intel, I.B.M., Johnson & Johnson, Mellon Financial, Northern Trust, Wells Fargo and Yahoo (Tuesday); Abbott Laboratories, Commerce Bancorp, E*Trade Financial, eBay, JPMorgan Chase, Motorola, PNC Financial Services, Allstate, Bank of New York, Tribune and United Technologies (Wednesday); Advanced Micro Devices, Altria Group, Continental Airlines, D. R. Horton, First Data, Gannett, Google, Merck, Merrill Lynch, Nokia, Schering-Plough, Southwest Airlines, UnitedHealth Group and Wyeth (Thursday); Caterpillar, Honeywell, McDonald\u2019s, SAP, Schlumberger and Xerox (Friday)."", ""print_section"": ""C"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Looking Ahead"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-04-16T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By The New York Times"", ""person"": [], ""organization"": ""The New York Times""}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d6e6c5c4-a42d-5d74-a778-a389e30a6ec1"", ""word_count"": 194, ""uri"": ""nyt://article/d6e6c5c4-a42d-5d74-a778-a389e30a6ec1""}"
2007-05-14,"[{""abstract"": ""Mylan Laboratories has agreed to buy the generic drug unit of Merck for $6.7 billion in cash."", ""web_url"": ""https://www.nytimes.com/2007/05/14/business/14drugs.html"", ""snippet"": ""Mylan Laboratories has agreed to buy the generic drug unit of Merck for $6.7 billion in cash."", ""lead_paragraph"": ""Mylan Laboratories has agreed to buy the generic drug unit of Merck, the German drug maker, for 4.9 billion euros ($6.7 billion) in cash."", ""print_section"": ""C"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Mylan Labs in Deal to Buy German Generic Drug Unit"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Mylan Labs in Deal to Buy German Generic Drug Unit"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mylan Laboratories Incorporated"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Pennsylvania"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic and Brand Name Products"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2007-05-14T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/68aa91a1-d449-5125-a584-19b609cdd093"", ""word_count"": 447, ""uri"": ""nyt://article/68aa91a1-d449-5125-a584-19b609cdd093""}, {""abstract"": ""Mylan Laboratories has agreed to buy the generic drug unit of Merck, the German drug maker, for 4.9 billion euros ($6.7 billion) in cash. The acquisition will make Mylan the world\u2019s third-largest maker of copycat versions of drugs, after Teva Pharmaceuticals of Israel and Novartis of Switzerland."", ""web_url"": ""https://dealbook.nytimes.com/2007/05/14/mylan-labs-in-deal-to-buy-german-generic-drug-unit/"", ""snippet"": """", ""lead_paragraph"": ""Mylan Laboratories has agreed to buy the generic drug unit of Merck, the German drug maker, for 4.9 billion euros ($6.7 billion) in cash. The acquisition will make Mylan the world\u2019s third-largest maker of copycat versions of drugs, after Teva Pharmaceuticals of Israel and Novartis of Switzerland."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Mylan Labs in Deal to Buy German Generic Drug Unit"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-05-14T12:00:41+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c79e226d-c5a7-5f57-b251-c9fe6a13a8cc"", ""word_count"": 114, ""uri"": ""nyt://article/c79e226d-c5a7-5f57-b251-c9fe6a13a8cc""}]"
2007-05-21,"{""abstract"": ""Europe\u2019s largest engineering company named Peter L\u00f6scher as its new chief executive."", ""web_url"": ""https://www.nytimes.com/2007/05/21/business/worldbusiness/21siemens.html"", ""snippet"": ""Europe\u2019s largest engineering company named Peter L\u00f6scher as its new chief executive."", ""lead_paragraph"": ""MUNICH, May 20 (Bloomberg News) \u2014 Siemens, Europe\u2019s largest engineering company, named Peter L\u00f6scher, an executive of the American drug maker Merck, as its chief executive, to succeed Klaus Kleinfeld, who resigned after less than three years because of a bribery investigation on his watch."", ""print_section"": ""C"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""A Battered Siemens Names a New Chief"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""A Battered Siemens Names a New Chief"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Kleinfeld, Klaus"", ""rank"": 2, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Europe"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Appointments and Executive Changes"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-05-21T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""World Business"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a4adfd6c-7437-5300-b2cf-9b3c4c92bede"", ""word_count"": 249, ""uri"": ""nyt://article/a4adfd6c-7437-5300-b2cf-9b3c4c92bede""}"
2007-06-06,"{""abstract"": ""A judge reversed himself and awarded $1.6 million to a former F.B.I. agent who blamed the drug for his heart attack."", ""web_url"": ""https://www.nytimes.com/2007/06/06/business/06vioxx.html"", ""snippet"": ""A judge reversed himself and awarded $1.6 million to a former F.B.I. agent who blamed the drug for his heart attack."", ""lead_paragraph"": "" A judge who threw out a $51 million damage award against Merck last year over its Vioxx painkiller reversed himself and awarded $1.6 million to the plaintiff, a former F.B.I. agent who blamed the drug for his heart attack."", ""print_section"": ""C"", ""print_page"": ""8"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Vioxx Damage Award"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Vioxx Damage Award"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Decisions and Verdicts"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-06-06T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ab833ee9-e5fa-56ed-b7e9-f7ea64ac8238"", ""word_count"": 151, ""uri"": ""nyt://article/ab833ee9-e5fa-56ed-b7e9-f7ea64ac8238""}"
2007-07-24,"{""abstract"": ""The company reported strong second-quarter results and said its profits for all of 2007 would beat analysts\u2019 expectations."", ""web_url"": ""https://www.nytimes.com/2007/07/24/business/24merck.html"", ""snippet"": ""The company reported strong second-quarter results and said its profits for all of 2007 would beat analysts\u2019 expectations."", ""lead_paragraph"": ""Continuing its impressive two-year-long turnaround, Merck reported strong second-quarter results and said its profits for all of 2007 would easily beat analysts\u2019 expectations."", ""print_section"": ""C"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Another Quarter of Strong Results by Merck"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Another Quarter of Strong Results by Merck"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Gardasil (Vaccine)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sales"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2007-07-24T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d9d5e6a6-aa99-51c4-bd71-58a6938ba464"", ""word_count"": 664, ""uri"": ""nyt://article/d9d5e6a6-aa99-51c4-bd71-58a6938ba464""}"
2007-08-21,"{""abstract"": ""No one who has sued Merck over heart attacks or strokes suffered after taking Vioxx has received payments."", ""web_url"": ""https://www.nytimes.com/2007/08/21/business/21merck.html"", ""snippet"": ""No one who has sued Merck over heart attacks or strokes suffered after taking Vioxx has received payments."", ""lead_paragraph"": ""KEENE, Tex. \u2014 In Carol Ernst\u2019s eyes, two years ago she won a measure of justice. "", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/08/21/business/21merck.75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/08/21/business/21merck.75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Plaintiffs Find Payday Elusive in Vioxx Cases"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Plaintiffs Find Payday Elusive In Vioxx Suits"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-08-21T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4400883a-2cb3-5888-ac3e-c83365a2bb3a"", ""word_count"": 1589, ""uri"": ""nyt://article/4400883a-2cb3-5888-ac3e-c83365a2bb3a""}"
2007-10-23,"{""abstract"": ""After an early morning skid, markets rebounded, boosted by an optimistic earnings report from Merck and a more favorable outlook for the technology sector."", ""web_url"": ""https://www.nytimes.com/2007/10/23/business/23stox.html"", ""snippet"": ""After an early morning skid, markets rebounded, boosted by an optimistic earnings report from Merck and a more favorable outlook for the technology sector."", ""lead_paragraph"": ""Fears of a continued stock market decline were eased yesterday as the major American indexes stabilized after an early morning skid and posted modest gains on the first trading day after Friday\u2019s steep sell-off."", ""print_section"": ""C"", ""print_page"": ""10"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Earnings Reports Give Markets a Respite"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Earnings Reports Give Markets a Respite"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Dow Jones Stock Average"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-10-23T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael M. Grynbaum"", ""person"": [{""firstname"": ""Michael"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2125c8bf-8fc7-576e-8789-2d6207d3c6a5"", ""word_count"": 459, ""uri"": ""nyt://article/2125c8bf-8fc7-576e-8789-2d6207d3c6a5""}"
2007-11-01,"{""abstract"": ""In an move to target the many adults who have not been vaccinated against hepatitis B, Merck has licensed a new, potentially more powerful vaccine against the disease. "", ""web_url"": ""https://www.nytimes.com/2007/11/01/business/01vaccine.html"", ""snippet"": ""In an move to target the many adults who have not been vaccinated against hepatitis B, Merck has licensed a new, potentially more powerful vaccine against the disease. "", ""lead_paragraph"": ""Merck has licensed the exclusive worldwide rights to sell a new, potentially more powerful vaccine against hepatitis B from Dynavax Technologies Corporation, a biotechnology company that is exploiting new findings about how the immune system works. "", ""print_section"": ""C"", ""print_page"": ""11"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Buys License to Sell New Vaccine for Hepatitis"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Buys License to Sell New Vaccine for Hepatitis"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hepatitis"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-11-01T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/0e1ea81f-d1d9-54d9-885d-cc5e7c3d348a"", ""word_count"": 360, ""uri"": ""nyt://article/0e1ea81f-d1d9-54d9-885d-cc5e7c3d348a""}"
2007-11-03,"{""abstract"": ""Many patients on the cholesterol drug are switching to a cheaper alternative, but Pfizer is not letting its flagship product go down without a fight."", ""web_url"": ""https://www.nytimes.com/2007/11/03/business/03generic.html"", ""snippet"": ""Many patients on the cholesterol drug are switching to a cheaper alternative, but Pfizer is not letting its flagship product go down without a fight."", ""lead_paragraph"": ""It is shaping up to be the biggest shift yet to a generic drug, potentially saving the nation $2 billion a year or more in prescription costs. "", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Maker of Lipitor Digs in to Fight Generic Rival"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Lipitor Maker Digs In to Fight Generic Rival"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Statins (Cholesterol-Lowering Drugs)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic and Brand Name Products"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2007-11-03T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Saul and Alex Berenson"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8bfa5295-d6cd-525e-9ce8-4733665c60fe"", ""word_count"": 1461, ""uri"": ""nyt://article/8bfa5295-d6cd-525e-9ce8-4733665c60fe""}"
2007-11-09,"[{""abstract"": ""Merck has agreed to settle 27,000 lawsuits by people who claim they or their family members suffered injury or died after taking the pain medication."", ""web_url"": ""https://www.nytimes.com/2007/11/09/business/09merck.html"", ""snippet"": ""Merck has agreed to settle 27,000 lawsuits by people who claim they or their family members suffered injury or died after taking the pain medication."", ""lead_paragraph"": ""Three years after withdrawing its pain medication Vioxx from the market, Merck has agreed to pay $4.85 billion to settle 27,000 lawsuits by people who claim they or their family members suffered injury or died after taking the drug, according to two lawyers with direct knowledge of the matter."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Agrees to Settle Vioxx Suits for $4.85 Billion"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Is Said to Agree to Pay $4.85 Billion for Vioxx Claims"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-11-09T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6dea76e7-0223-5f74-9cd1-46e349d1be84"", ""word_count"": 822, ""uri"": ""nyt://article/6dea76e7-0223-5f74-9cd1-46e349d1be84""}, {""abstract"": ""The settlement, one of the largest ever in civil litigation, affects 27,000 lawsuits over the pain medication."", ""web_url"": ""https://www.nytimes.com/2007/11/09/business/09cnd-merck.html"", ""snippet"": ""The settlement, one of the largest ever in civil litigation, affects 27,000 lawsuits over the pain medication."", ""lead_paragraph"": ""Three years after withdrawing its pain medication Vioxx from the market, Merck announced today that it will pay $4.85 billion to settle 27,000 lawsuits by people who contend they or their family members suffered injury or died after taking the drug."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Agrees to Pay $4.85 Billion in Vioxx Claims"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Agrees to Pay $4.85 Billion for Vioxx Claims"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2007-11-09T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d148f637-d296-57f5-bcf3-cc323ab0d240"", ""word_count"": 782, ""uri"": ""nyt://article/d148f637-d296-57f5-bcf3-cc323ab0d240""}]"
2007-11-10,"{""abstract"": ""While Friday\u2019s settlement of Vioxx lawsuits at $4.85 billion seems steep, two years ago some analysts estimated that it would cost Merck as much as $25 billion."", ""web_url"": ""https://www.nytimes.com/2007/11/10/business/10merck.html"", ""snippet"": ""While Friday\u2019s settlement of Vioxx lawsuits at $4.85 billion seems steep, two years ago some analysts estimated that it would cost Merck as much as $25 billion."", ""lead_paragraph"": ""For the drug maker Merck to pay almost $5 billion to settle lawsuits from people who contended that the painkiller Vioxx caused their heart attacks and strokes may not seem like a corporate victory."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Analysts See Merck Victory in Vioxx Settlement"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Analysts See Merck Victory In Vioxx Deal"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Decisions and Verdicts"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2007-11-10T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/312525c2-c0f1-5b94-8304-92103cb8e286"", ""word_count"": 1521, ""uri"": ""nyt://article/312525c2-c0f1-5b94-8304-92103cb8e286""}"
2007-11-17,"{""abstract"": ""Is a mass tort really the right mechanism to settle disputes about product safety, or to punish corporate wrongdoing?"", ""web_url"": ""https://www.nytimes.com/2007/11/17/business/17nocera.html"", ""snippet"": ""Is a mass tort really the right mechanism to settle disputes about product safety, or to punish corporate wrongdoing?"", ""lead_paragraph"": ""They had the kits ready to go. The \u201ctrial package,\u201d they called it."", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Forget Fair; It\u2019s Litigation as Usual"", ""kicker"": ""Talking Business"", ""content_kicker"": null, ""print_headline"": ""Forget Fair; It\u2019s Litigation As Usual"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-11-17T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Joe Nocera"", ""person"": [{""firstname"": ""Joe"", ""middlename"": null, ""lastname"": ""Nocera"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/90004e55-8d7f-5324-a840-e3578582b663"", ""word_count"": 1827, ""uri"": ""nyt://article/90004e55-8d7f-5324-a840-e3578582b663""}"
2007-11-21,"{""abstract"": ""A delay in publishing the results of trials on cholesterol  drugs is raising questions for the drug industry."", ""web_url"": ""https://www.nytimes.com/2007/11/21/business/21drug.html"", ""snippet"": ""A delay in publishing the results of trials on cholesterol  drugs is raising questions for the drug industry."", ""lead_paragraph"": ""Prescriptions for the cholesterol-lowering drugs Zetia and Vytorin are written for almost 800,000 Americans every week, at a cost this year of about $4 billion. Yet it still is not clear how well the drugs work."", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/11/21/business/21drug.xlarge1.jpg"", ""height"": 350, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2007/11/21/business/21drug.xlarge1.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 350}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/11/21/business/21drug.751.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/11/21/business/21drug.751.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Cardiologists Question Delay of Data on 2 Drugs "", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""After a Trial, Silence"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Schering Plough Corp"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tests and Testing"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2007-11-21T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/117c18c3-ad1f-5aaa-9ac3-87fecc82eab7"", ""word_count"": 1548, ""uri"": ""nyt://article/117c18c3-ad1f-5aaa-9ac3-87fecc82eab7""}"
2007-12-12,"{""abstract"": ""A Congressional committee is investigating Merck and Schering-Plough for their handling of a critical clinical trial of Zetia, their blockbuster cholesterol-lowering drug."", ""web_url"": ""https://www.nytimes.com/2007/12/12/business/12zetia.html"", ""snippet"": ""A Congressional committee is investigating Merck and Schering-Plough for their handling of a critical clinical trial of Zetia, their blockbuster cholesterol-lowering drug."", ""lead_paragraph"": ""A Congressional committee is investigating Merck and Schering-Plough for their handling of a critical clinical trial of Zetia, their blockbuster cholesterol-lowering drug. "", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Trial of Cholesterol Drug Gets House Scrutiny"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""House Panel Scrutinizes Trial of Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Schering Plough Corp"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tests and Testing"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Senate"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""House of Representatives"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2007-12-12T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/331574a8-ad12-5651-8c47-638f4ed99d58"", ""word_count"": 576, ""uri"": ""nyt://article/331574a8-ad12-5651-8c47-638f4ed99d58""}"
2007-12-20,"{""abstract"": ""Several plaintiffs\u2019 lawyers have asked the judge overseeing the $4.85 billion settlement to allow them to keep some of their clients outside the settlement while others accept it."", ""web_url"": ""https://www.nytimes.com/2007/12/20/business/20cnd-vioxx.html"", ""snippet"": ""Several plaintiffs\u2019 lawyers have asked the judge overseeing the $4.85 billion settlement to allow them to keep some of their clients outside the settlement while others accept it."", ""lead_paragraph"": ""Several plaintiffs\u2019 lawyers have asked the federal judge overseeing the $4.85 billion Vioxx settlement to give them the freedom to keep some of their clients outside the settlement while still allowing other clients to accept it."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Some Lawyers Seek Changes in Vioxx Settlement"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2007-12-20T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e5aecccc-7965-5f52-93f5-2758837efb7d"", ""word_count"": 678, ""uri"": ""nyt://article/e5aecccc-7965-5f52-93f5-2758837efb7d""}"
2007-12-21,"[{""abstract"": ""Several plaintiffs\u2019 lawyers have asked that some of their clients be allowed to reject the $4.85 billion Vioxx settlement as others accept it."", ""web_url"": ""https://www.nytimes.com/2007/12/21/business/21vioxx.html"", ""snippet"": ""Several plaintiffs\u2019 lawyers have asked that some of their clients be allowed to reject the $4.85 billion Vioxx settlement as others accept it."", ""lead_paragraph"": ""Several plaintiffs\u2019 lawyers have asked the federal judge overseeing the $4.85 billion Vioxx settlement to give them the freedom to keep some of their clients outside the settlement while allowing other clients to accept it."", ""print_section"": ""C"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Some Lawyers Seek Changes in Vioxx Settlement"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Lawyers Seek to Alter Settlement Over Vioxx"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2007-12-21T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1d7253dd-4830-5f9f-bad0-516194a61e7f"", ""word_count"": 669, ""uri"": ""nyt://article/1d7253dd-4830-5f9f-bad0-516194a61e7f""}, {""abstract"": ""New evidence shows that drug makers Merck and Schering-Plough never published several studies that raised questions about a cholesterol drug\u2019s risks to the liver."", ""web_url"": ""https://www.nytimes.com/2007/12/21/business/21drug.html"", ""snippet"": ""New evidence shows that drug makers Merck and Schering-Plough never published several studies that raised questions about a cholesterol drug\u2019s risks to the liver."", ""lead_paragraph"": ""New evidence shows that the drug makers Merck and Schering-Plough have conducted several studies of their popular cholesterol medicine Zetia that raise questions about its risks to the liver, but the companies have never published those results."", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Data About Zetia Risks Was Not Fully Revealed"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Data About Zetia Risks Was Not Fully Revealed"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Schering Plough Corp"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tests and Testing"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zetia (Drug)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2007-12-21T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e7b4a4c0-a768-5677-bc51-a8500034cb40"", ""word_count"": 1634, ""uri"": ""nyt://article/e7b4a4c0-a768-5677-bc51-a8500034cb40""}]"
2008-01-04,"{""abstract"": ""Merck agreed to pay a Swiss company, Addex Pharmaceuticals, as much as $702 million to help develop a new schizophrenia drug."", ""web_url"": ""https://www.nytimes.com/2008/01/04/business/worldbusiness/04drug.html"", ""snippet"": ""Merck agreed to pay a Swiss company, Addex Pharmaceuticals, as much as $702 million to help develop a new schizophrenia drug."", ""lead_paragraph"": ""Merck & Company agreed on Thursday to pay a Swiss company, Addex Pharmaceuticals, as much as $702 million to help develop a new schizophrenia drug."", ""print_section"": ""C"", ""print_page"": ""8"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Makes Deal to Develop Schizophrenia Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Makes Deal to Develop Schizophrenia Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mental Health and Disorders"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Schizophrenia"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2008-01-04T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""World Business"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/aecd63b6-8b8d-5612-a1b8-96538bcf5610"", ""word_count"": 237, ""uri"": ""nyt://article/aecd63b6-8b8d-5612-a1b8-96538bcf5610""}"
2008-01-14,"{""abstract"": ""The outcome of a trial that failed to show that Zetia has any medical benefits adds to concerns over the drug."", ""web_url"": ""https://www.nytimes.com/2008/01/14/business/14cnd-drug.html"", ""snippet"": ""The outcome of a trial that failed to show that Zetia has any medical benefits adds to concerns over the drug."", ""lead_paragraph"": "" A clinical trial of Zetia, a cholesterol-lowering drug prescribed to about 1 million people a week, failed to show that the drug has any medical benefits, Merck and Schering-Plough said on Monday."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Drug Has No Benefit in Trial, Makers Say"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Schering Plough Corp"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zetia (Drug)"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2008-01-14T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/0970811f-63b0-5777-a7d3-97605dcb278c"", ""word_count"": 845, ""uri"": ""nyt://article/0970811f-63b0-5777-a7d3-97605dcb278c""}"
2008-01-15,"{""abstract"": ""A clinical trial of Zetia, a widely used cholesterol drug, has raised questions about its effectiveness and the behavior of pharmaceutical companies that conducted the study."", ""web_url"": ""https://www.nytimes.com/2008/01/15/business/15drug.html"", ""snippet"": ""A clinical trial of Zetia, a widely used cholesterol drug, has raised questions about its effectiveness and the behavior of pharmaceutical companies that conducted the study."", ""lead_paragraph"": ""A clinical trial of a widely used cholesterol drug has raised questions both about the medicine\u2019s effectiveness and about the behavior of the pharmaceutical companies that conducted the study, cardiologists said Monday."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Study Reveals Doubt on Drug for Cholesterol"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Study Reveals Doubt on Drug For Cholesterol"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Schering Plough Corp"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Statins (Cholesterol-Lowering Drugs)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zetia (Drug)"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2008-01-15T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/62df8d52-4050-51a6-988b-6b0493e52645"", ""word_count"": 1242, ""uri"": ""nyt://article/62df8d52-4050-51a6-988b-6b0493e52645""}"
2008-01-17,"{""abstract"": ""Following results of recent clinical trials on popular cholesterol drugs, cardiologists are questioning whether a patient\u2019s cholesterol should be all that matters."", ""web_url"": ""https://www.nytimes.com/2008/01/17/business/17drug.html"", ""snippet"": ""Following results of recent clinical trials on popular cholesterol drugs, cardiologists are questioning whether a patient\u2019s cholesterol should be all that matters."", ""lead_paragraph"": ""For decades, the theory that lowering cholesterol is always beneficial has been a core principle of cardiology. It has been accepted by doctors and used by drug makers to win quick approval for new medicines to reduce cholesterol."", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""New Questions on Treating Cholesterol"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Cholesterol As a Danger Has Skeptics"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Statins (Cholesterol-Lowering Drugs)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zetia (Drug)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMERICAN HEART ASSN"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2008-01-17T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/569bbbb7-d9f0-5e08-a31e-e7fc24461547"", ""word_count"": 1009, ""uri"": ""nyt://article/569bbbb7-d9f0-5e08-a31e-e7fc24461547""}"
2008-01-24,"{""abstract"": ""The American Heart Association defended the drug Vytorin, an expensive drug combination for cholesterol, which was shown last week to work no better than Zocor, a cheaper alternative."", ""web_url"": ""https://www.nytimes.com/2008/01/24/business/24heart.html"", ""snippet"": ""The American Heart Association defended the drug Vytorin, an expensive drug combination for cholesterol, which was shown last week to work no better than Zocor, a cheaper alternative."", ""lead_paragraph"": ""After a study last week showed Vytorin, an expensive combination of two drugs for cholesterol, worked no better than cheap Zocor alone in reducing artery plaque that can lead to heart attacks, the American Heart Association came to the drug\u2019s defense."", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Heart Group Backs Drug Made by Ally"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Heart Group Backs Drug Made by Ally"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Schering Plough Corp"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Heart"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMERICAN HEART ASSN"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2008-01-24T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/fdda4c0e-4573-5baf-8202-445bd3440343"", ""word_count"": 674, ""uri"": ""nyt://article/fdda4c0e-4573-5baf-8202-445bd3440343""}"
2008-01-25,"{""abstract"": ""The biotechnology company said Thursday that its experimental osteoporosis drug proved superior to Fosamax from Merck in a clinical trial."", ""web_url"": ""https://www.nytimes.com/2008/01/25/business/25amgen.html"", ""snippet"": ""The biotechnology company said Thursday that its experimental osteoporosis drug proved superior to Fosamax from Merck in a clinical trial."", ""lead_paragraph"": ""Amgen, the biotechnology company, said Thursday that its experimental osteoporosis drug, the brightest hope in its product pipeline, proved superior to Fosamax from Merck in a clinical trial. "", ""print_section"": ""C"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Amgen Posts Weak Results, but Hails Osteoporosis Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Amgen Posts Weak Results, But Hails Osteoporosis Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2008-01-25T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/466eb8e5-4fed-5d6f-b498-b281ac7892b2"", ""word_count"": 554, ""uri"": ""nyt://article/466eb8e5-4fed-5d6f-b498-b281ac7892b2""}"
2008-03-31,"{""abstract"": ""The drugs Vytorin and Zetia may not work and should be used only as a last resort, The New England Journal of Medicine and a panel of cardiologists at a major cardiology conference said on Sunday."", ""web_url"": ""https://www.nytimes.com/2008/03/31/business/31drug-web.html"", ""snippet"": ""The drugs Vytorin and Zetia may not work and should be used only as a last resort, The New England Journal of Medicine and a panel of cardiologists at a major cardiology conference said on Sunday."", ""lead_paragraph"": ""CHICAGO \u0097 Two widely prescribed cholesterol-lowering drugs, Vytorin and Zetia, may not work and should be used only as a last resort, a panel of four cardiologists told an audience of more than 5,000 people at a major cardiology conference on Sunday."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Doubt Cast on 2 Drugs Used to Lower Cholesterol"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""New England Journal of Medicine"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Schering Plough Corp"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Statins (Cholesterol-Lowering Drugs)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tests and Testing"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zetia (Drug)"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2008-03-31T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/bbaf3094-1af4-594a-b679-60cac9522005"", ""word_count"": 824, ""uri"": ""nyt://article/bbaf3094-1af4-594a-b679-60cac9522005""}"
2008-04-01,"{""abstract"": ""A doctor who led a key trial of two heart drugs accused their makers, Merck and Schering-Plough, last July of hiding the negative results."", ""web_url"": ""https://www.nytimes.com/2008/04/01/business/01drug.html"", ""snippet"": ""A doctor who led a key trial of two heart drugs accused their makers, Merck and Schering-Plough, last July of hiding the negative results."", ""lead_paragraph"": ""CHICAGO \u0097 The lead outside investigator on a crucial trial of two widely used heart drugs said in an e-mail message last July that Merck and Schering-Plough, the companies that make the drugs, were deliberately delaying the release of the trial results \u201cto hide something.\u201d"", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Accusations of Delays in Releasing Drug Results"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Accusations Of Delays In Releasing Drug Results"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Schering Plough Corp"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Statins (Cholesterol-Lowering Drugs)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tests and Testing"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zetia (Drug)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2008-04-01T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f4dff993-5b9f-5e32-930f-4a0024f54795"", ""word_count"": 1006, ""uri"": ""nyt://article/f4dff993-5b9f-5e32-930f-4a0024f54795""}"
2008-04-15,"{""abstract"": ""Merck drafted dozens of studies for a best-selling drug, then lined up prestigious doctors to put their names on the reports before publication, according to an article in a leading medical journal."", ""web_url"": ""https://www.nytimes.com/2008/04/15/business/15cnd-vioxx.html"", ""snippet"": ""Merck drafted dozens of studies for a best-selling drug, then lined up prestigious doctors to put their names on the reports before publication, according to an article in a leading medical journal."", ""lead_paragraph"": ""The drug maker Merck drafted dozens of research studies for a best-selling drug, then lined up prestigious doctors to put their names on the reports before publication, according to an article to be published Wednesday in a leading medical journal."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Ghostwriters Used in Vioxx Studies, Article Says"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Ghostwriters Used Extensively in Vioxx Research Studies, Article Says"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""PUBLICATIONS"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2008-04-15T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1f376c37-0c46-59f5-a200-92e9d62cc5df"", ""word_count"": 1417, ""uri"": ""nyt://article/1f376c37-0c46-59f5-a200-92e9d62cc5df""}"
2008-04-16,"{""abstract"": ""Documents unearthed in lawsuits over the pain drug Vioxx provide a rare, detailed look at the industry practice of ghostwriting medical research studies."", ""web_url"": ""https://www.nytimes.com/2008/04/16/business/16vioxx.html"", ""snippet"": ""Documents unearthed in lawsuits over the pain drug Vioxx provide a rare, detailed look at the industry practice of ghostwriting medical research studies."", ""lead_paragraph"": ""The drug maker Merck drafted dozens of research studies for a best-selling drug, then lined up prestigious doctors to put their names on the reports before publication, according to an article to be published Wednesday in a leading medical journal."", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Wrote Drug Studies for Doctors"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Wrote Drug Studies For Doctors"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2008-04-16T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9189fee6-694b-5f71-bd5d-7e95bd574012"", ""word_count"": 1002, ""uri"": ""nyt://article/9189fee6-694b-5f71-bd5d-7e95bd574012""}"
2008-04-19,"{""abstract"": ""A report indicating that Merck used ghostwriters to produce articles in support of its drug Vioxx has galvanized opponents to a proposal that would relax some restrictions on drug promotion."", ""web_url"": ""https://www.nytimes.com/2008/04/19/business/19ghost.html"", ""snippet"": ""A report indicating that Merck used ghostwriters to produce articles in support of its drug Vioxx has galvanized opponents to a proposal that would relax some restrictions on drug promotion."", ""lead_paragraph"": ""The pharmaceutical industry glimpsed its own ghost this week, and the apparition could not have arrived at a worse time for drug makers. "", ""print_section"": ""C"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""F.D.A. Plan on Medical Articles Takes More Heat"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Setback for Effort to Ease Rules on Promoting Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Ghostwriting"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2008-04-19T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/180dd668-d7aa-558b-8c7e-9c7ae7353f4a"", ""word_count"": 1015, ""uri"": ""nyt://article/180dd668-d7aa-558b-8c7e-9c7ae7353f4a""}"
2008-04-21,"{""abstract"": ""CNBC interviews Richard T. Clark, chief executive of Merck, on his company's earnings."", ""web_url"": ""https://www.nytimes.com/video/business/1194817114451/merck-s-chief-discusses-earnings.html"", ""snippet"": ""CNBC interviews Richard T. Clark, chief executive of Merck, on his company's earnings."", ""lead_paragraph"": ""CNBC interviews Richard T. Clark, chief executive of Merck, on his company's earnings."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2008/04/21/business/MerckChiefEarns.75x75.fr.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2008/04/21/business/MerckChiefEarns.75x75.fr.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Merck's Chief Discusses Earnings"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2008-04-21T16:53:05+0000"", ""document_type"": ""multimedia"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": """", ""person"": [], ""organization"": null}, ""type_of_material"": ""Video"", ""_id"": ""nyt://video/d8fd2d16-f7ad-5e46-b6ec-6298d20845bf"", ""word_count"": 0, ""uri"": ""nyt://video/d8fd2d16-f7ad-5e46-b6ec-6298d20845bf""}"
2008-05-30,"{""abstract"": ""The major victories for Merck pushed the litigation over Vioxx closer to conclusion and highlighted the difficulty that plaintiffs\u2019 lawyers are having in winning lawsuits against big drug companies."", ""web_url"": ""https://www.nytimes.com/2008/05/30/business/30drug.html"", ""snippet"": ""The major victories for Merck pushed the litigation over Vioxx closer to conclusion and highlighted the difficulty that plaintiffs\u2019 lawyers are having in winning lawsuits against big drug companies."", ""lead_paragraph"": ""Two major court victories for Merck on Thursday pushed the litigation over the painkiller Vioxx closer to conclusion and highlighted the increasing difficulty that plaintiffs\u2019 lawyers were having in winning lawsuits against big drug companies."", ""print_section"": ""C"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Courts Reject Two Major Vioxx Verdicts"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Courts Reject Two Major Vioxx Verdicts"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2008-05-30T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4627165e-35bb-51f0-9b7d-57f9aa3f77c3"", ""word_count"": 692, ""uri"": ""nyt://article/4627165e-35bb-51f0-9b7d-57f9aa3f77c3""}"
2008-07-22,"{""abstract"": ""The cholesterol-lowering drug Vytorin did not help people with heart-valve disease avoid further heart problems but did appear to increase their risk of cancer, scientists reported Monday."", ""web_url"": ""https://www.nytimes.com/2008/07/22/business/22drug.html"", ""snippet"": ""The cholesterol-lowering drug Vytorin did not help people with heart-valve disease avoid further heart problems but did appear to increase their risk of cancer, scientists reported Monday."", ""lead_paragraph"": ""In a clinical trial, the cholesterol-lowering drug Vytorin did not help people with heart-valve disease avoid further heart problems but did appear to increase their risk of cancer, scientists reported Monday."", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2008/07/22/business/22drug_600.jpg"", ""height"": 310, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2008/07/22/business/22drug_600.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 310}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2008/07/22/business/22drug_75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2008/07/22/business/22drug_75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Trial Intensifies Concerns About Safety of Vytorin"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Intensified Concerns On Vytorin"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Schering Plough Corp"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2008-07-22T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/51526e06-37f3-5046-8c0c-6aa47a8c6d3f"", ""word_count"": 1028, ""uri"": ""nyt://article/51526e06-37f3-5046-8c0c-6aa47a8c6d3f""}"
2008-09-16,"{""abstract"": ""Amgen\u2019s experimental bone drug reduced the risk of spinal fractures in women with osteoporosis by 68 percent in a pivotal clinical trial."", ""web_url"": ""https://www.nytimes.com/2008/09/17/business/17drug.html"", ""snippet"": ""Amgen\u2019s experimental bone drug reduced the risk of spinal fractures in women with osteoporosis by 68 percent in a pivotal clinical trial."", ""lead_paragraph"": ""Amgen\u2019s experimental bone drug reduced the risk of spinal fractures in women with osteoporosis by 68 percent in a pivotal clinical trial, a robust result that raises hopes that the drug can help restore the luster of the embattled biotechnology company. "", ""print_section"": ""C"", ""print_page"": ""12"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Good Results for Bone Drug Buoy Amgen"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Good Results for Bone Drug Buoy Amgen"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Tests and Testing"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis A.G"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Credit Suisse Group"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding Ltd"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Procter & Gamble Co"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""S.A.nofi-Aventis S.A"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Osteoporosis"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 11, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ANEMIA"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2008-09-16T15:05:16+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c0826873-d7ea-5f37-8453-d7017d70db6f"", ""word_count"": 970, ""uri"": ""nyt://article/c0826873-d7ea-5f37-8453-d7017d70db6f""}"
2008-10-22,"{""abstract"": ""Hurt by declining sales of some of its biggest drugs and vaccines, Merck said that it would cut another 7,200 jobs, or 12 percent of its work force, in its second revamping in three years."", ""web_url"": ""https://www.nytimes.com/2008/10/23/business/23merck.html"", ""snippet"": ""Hurt by declining sales of some of its biggest drugs and vaccines, Merck said that it would cut another 7,200 jobs, or 12 percent of its work force, in its second revamping in three years."", ""lead_paragraph"": ""Merck, hurt by declining sales of some of its biggest drugs and vaccines, said on Wednesday that it would cut 7,200 more jobs, or more than 12 percent of its work force, its second revamping in three years. "", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Plans to Cut 12% of Work Force as Its Sales and Profit Fall"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Plans to Cut 12% of Work Force as Its Sales and Profit Fall"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Layoffs and Job Reductions"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2008-10-22T19:56:55+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b8a3a94a-216c-5d7f-bf10-dafce0388567"", ""word_count"": 815, ""uri"": ""nyt://article/b8a3a94a-216c-5d7f-bf10-dafce0388567""}"
2009-03-09,"[{""abstract"": ""Merck, facing patent expirations, is hoping to shore up its research pipeline and expand its global reach."", ""web_url"": ""https://www.nytimes.com/2009/03/10/business/10drug.html"", ""snippet"": ""Merck, facing patent expirations, is hoping to shore up its research pipeline and expand its global reach."", ""lead_paragraph"": ""A drug deal that is mainly about the drugs."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck to Buy Schering-Plough for $41.1 Billion"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Refills Pipeline"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Schering Plough Corp"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2009-03-09T10:32:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ebc1b0b7-e00e-5f5a-a6ff-0e5f9c3e80ea"", ""word_count"": 1265, ""uri"": ""nyt://article/ebc1b0b7-e00e-5f5a-a6ff-0e5f9c3e80ea""}, {""abstract"": ""Merck, the American pharmaceutical giant, will pay $41 billion to acquire its rival Schering-Plough, the two companies said Monday."", ""web_url"": ""https://dealbook.nytimes.com/2009/03/09/merck-to-buy-schering-plough-for-411-billion/"", ""snippet"": """", ""lead_paragraph"": ""Merck, the American pharmaceutical giant, will pay $41 billion to acquire its rival Schering-Plough, the two companies said Monday."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck to Buy Schering-Plough for $41.1 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-03-09T11:16:26+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/987621f3-3f05-5f22-9faa-159763b8d71c"", ""word_count"": 297, ""uri"": ""nyt://article/987621f3-3f05-5f22-9faa-159763b8d71c""}, {""abstract"": ""A reverse merger in biotechnology is meant to help a private company go public when the investment climate is poor for an initial public offering."", ""web_url"": ""https://www.nytimes.com/2009/03/10/business/10biocashside.html"", ""snippet"": ""A reverse merger in biotechnology is meant to help a private company go public when the investment climate is poor for an initial public offering."", ""lead_paragraph"": ""It is called a reverse merger. And for a failing public biotechnology company, it can represent one last roll of the dice. "", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Taking a Chance on a Reverse Merger"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Taking a Chance on a Reverse Merger"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Schering Plough Corp"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""NitroMed, Incorporated"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Biotechnology"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2009-03-09T21:34:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9a62ba71-ed36-5ec3-8a6a-d9ac8a6f2d76"", ""word_count"": 485, ""uri"": ""nyt://article/9a62ba71-ed36-5ec3-8a6a-d9ac8a6f2d76""}]"
2009-03-10,"[{""abstract"": ""With the healthcare mega-merger party in full swing, others may show up to take part in the festivities."", ""web_url"": ""https://dealbook.nytimes.com/2009/03/10/after-merck-deal-rivals-may-seek-to-fill-their-dance-cards/"", ""snippet"": """", ""lead_paragraph"": ""With the healthcare mega-merger party in full swing, others may show up to take part in the festivities."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""After Merck Deal, Rivals May Seek to Fill Their Dance Cards"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-03-10T10:45:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9a47eda6-a60a-5cc6-b0af-9aed048377d6"", ""word_count"": 89, ""uri"": ""nyt://article/9a47eda6-a60a-5cc6-b0af-9aed048377d6""}, {""abstract"": ""Two pharmaceutical companies, with headquarters a half-hour\u2019s drive apart on Interstate 78, form the backbone of the New Jersey communities they call home. Merck & Company, in Whitehouse Station, and Schering-Plough, in Kenilworth 34 miles to the east, provide jobs, tax revenue and a sense of identity in a state that some call America\u2019s medicine cabinet."", ""web_url"": ""https://dealbook.nytimes.com/2009/03/10/new-jersey-towns-worry-about-mergers-consequences/"", ""snippet"": """", ""lead_paragraph"": ""Two pharmaceutical companies, with headquarters a half-hour\u2019s drive apart on Interstate 78, form the backbone of the New Jersey communities they call home. Merck & Company, in Whitehouse Station, and Schering-Plough, in Kenilworth 34 miles to the east, provide jobs, tax revenue and a sense of identity in a state that some call America\u2019s medicine cabinet."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""New Jersey Towns Worry About Merger\u2019s Consequences"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-03-10T10:47:03+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ba6076c3-4942-5367-a372-437dc0766e0c"", ""word_count"": 687, ""uri"": ""nyt://article/ba6076c3-4942-5367-a372-437dc0766e0c""}, {""abstract"": ""If Johnson & Johnson \u2014 or anyone else, for that matter \u2014 is thinking about making a play for Schering-Plough, here\u2019s a number worth considering: $1.25 billion."", ""web_url"": ""https://dealbook.nytimes.com/2009/03/10/for-merck-and-schering-goodbye-could-cost-125-billion/"", ""snippet"": """", ""lead_paragraph"": ""If Johnson & Johnson \u2014 or anyone else, for that matter \u2014 is thinking about making a play for Schering-Plough, here\u2019s a number worth considering: $1.25 billion."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""For Merck and Schering, Goodbye Could Cost $1.25 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-03-10T16:10:28+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d2dee203-3219-5859-b9b5-382cee5ae8f1"", ""word_count"": 193, ""uri"": ""nyt://article/d2dee203-3219-5859-b9b5-382cee5ae8f1""}]"
2009-03-11,"{""abstract"": ""Merck filed the agreement for its acquisition of Schering-Plough with regulators on Tuesday. The agreement has many interesting provisions throughout, but I want to focus on the two most important items. "", ""web_url"": ""https://dealbook.nytimes.com/2009/03/11/merck-and-schering-ploughs-extreme-engineering/"", ""snippet"": """", ""lead_paragraph"": ""Merck filed the agreement for its acquisition of Schering-Plough with regulators on Tuesday. The agreement has many interesting provisions throughout, but I want to focus on the two most important items. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck and Schering-Plough\u2019s Extreme Engineering"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-03-11T13:30:30+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b1e8d8af-bf5a-5ecd-86bd-34cdd63b181b"", ""word_count"": 1647, ""uri"": ""nyt://article/b1e8d8af-bf5a-5ecd-86bd-34cdd63b181b""}"
2009-03-13,"{""abstract"": ""A change in Schering\u2019s ownership could set off a termination clause in a marketing pact and enable Johnson & Johnson to gain full rights to Remicade, a lucrative rheumatoid arthritis drug."", ""web_url"": ""https://www.nytimes.com/2009/03/13/business/13place.html"", ""snippet"": ""A change in Schering\u2019s ownership could set off a termination clause in a marketing pact and enable Johnson & Johnson to gain full rights to Remicade, a lucrative rheumatoid arthritis drug."", ""lead_paragraph"": ""HOW will Johnson & Johnson respond?"", ""print_section"": ""B"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/03/13/business/13place01-75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/03/13/business/13place01-75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Merck-Schering Merger Awaits Reaction From Johnson & Johnson"", ""kicker"": ""Market Place"", ""content_kicker"": null, ""print_headline"": ""Merck-Schering Merger Awaits Reaction From Johnson & Johnson"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Schering Plough Corp"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Remicade (Drug)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2009-03-13T00:26:38+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/acd33eb7-9388-515c-bd25-a7f7ed429988"", ""word_count"": 881, ""uri"": ""nyt://article/acd33eb7-9388-515c-bd25-a7f7ed429988""}"
2009-03-16,"{""abstract"": ""The $41 billion tie-up announced last week between Merck and Schering-Plough creates some interesting options for Johnson & Johnson. "", ""web_url"": ""https://dealbook.nytimes.com/2009/03/16/diagnosing-jjs-next-move/"", ""snippet"": """", ""lead_paragraph"": ""The $41 billion tie-up announced last week between Merck and Schering-Plough creates some interesting options for Johnson & Johnson. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Diagnosing J.&J.\u2019s Next Move"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-03-16T16:41:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/90c56ba0-256f-555f-90d0-e0dc3124de3a"", ""word_count"": 1346, ""uri"": ""nyt://article/90c56ba0-256f-555f-90d0-e0dc3124de3a""}"
2009-04-23,"{""abstract"": ""Some drug makers are backing up their products with discount deals or promises to pay if the drugs don\u2019t work."", ""web_url"": ""https://www.nytimes.com/2009/04/23/business/23cigna.html"", ""snippet"": ""Some drug makers are backing up their products with discount deals or promises to pay if the drugs don\u2019t work."", ""lead_paragraph"": ""Think of it as product guarantees by the drug industry."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Drug Deals Tie Prices to How Well Patients Do"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Drug Deals Tie Prices To How Well Patients Do"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Guarantees and Warranties"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cigna Corp"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2009-04-23T01:43:51+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8c74941e-71cd-5da9-9591-930eccd2f66c"", ""word_count"": 839, ""uri"": ""nyt://article/8c74941e-71cd-5da9-9591-930eccd2f66c""}"
2009-05-14,"[{""abstract"": ""A publication sponsored by Merck and including positive articles about its products comes to light in a lawsuit alleging misleading and deceptive practices."", ""web_url"": ""https://www.nytimes.com/2009/05/14/business/14vioxxside.html"", ""snippet"": ""A publication sponsored by Merck and including positive articles about its products comes to light in a lawsuit alleging misleading and deceptive practices."", ""lead_paragraph"": ""Pharmaceutical companies routinely offer doctors reprints of articles from medical journals that are favorable to their products."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Paid for Medical \u2018Journal\u2019 Without Disclosure"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Paid for Medical \u2018Journal\u2019 Without Disclosure"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Reed Elsevier N.V"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2009-05-14T00:58:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cd4980fc-025b-5e23-87d0-c00de9d5599b"", ""word_count"": 475, ""uri"": ""nyt://article/cd4980fc-025b-5e23-87d0-c00de9d5599b""}, {""abstract"": ""A class-action lawsuit over the strategies that Merck used to market its painkiller Vioxx in Australia is earning the American drug maker some bad publicity."", ""web_url"": ""https://www.nytimes.com/2009/05/14/business/14vioxx.html"", ""snippet"": ""A class-action lawsuit over the strategies that Merck used to market its painkiller Vioxx in Australia is earning the American drug maker some bad publicity."", ""lead_paragraph"": ""Australians have been riveted over the last month by a class-action lawsuit that is pulling back the curtain on strategies that the American drug giant Merck used in its international marketing of the painkiller Vioxx."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Trial Puts Spotlight on Merck"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Trial Puts Spotlight On Merck"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Australia"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2009-05-14T01:00:38+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/56137b64-4eff-5f2c-b2a8-46a91e61a7bc"", ""word_count"": 1081, ""uri"": ""nyt://article/56137b64-4eff-5f2c-b2a8-46a91e61a7bc""}]"
2009-05-21,"{""abstract"": ""Johnson & Johnson told Merck it plans to seek arbitration on whether it can pull out of a blockbuster drug partnership with Schering-Plough as that company sells itself to Merck for $41.1 billion, The Associated Press reported."", ""web_url"": ""https://dealbook.nytimes.com/2009/05/21/jj-seeks-to-arbitrate-schering-remicade-deal/"", ""snippet"": ""Johnson & Johnson told Merck it plans to seek arbitration on whether it can pull out of a blockbuster drug partnership with Schering-Plough as that company sells itself to Merck for $41.1 billion, The Associated Press reported."", ""lead_paragraph"": ""Johnson & Johnson told Merck it plans to seek arbitration on whether it can pull out of a blockbuster drug partnership with Schering-Plough as that company sells itself to Merck for $41.1 billion, The Associated Press reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""J&J Seeks to Arbitrate Schering Remicade Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-05-21T11:12:56+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/0ddabed3-068c-55be-b882-3847d6d803d8"", ""word_count"": 136, ""uri"": ""nyt://article/0ddabed3-068c-55be-b882-3847d6d803d8""}"
2009-05-27,"{""abstract"": ""The U.S. Supreme Court said on Tuesday that it would hear an appeal by Merck of a ruling that reinstated a securities fraud lawsuit involving the company\u2019s disclosures to investors about its withdrawn Vioxx pain drug."", ""web_url"": ""https://dealbook.nytimes.com/2009/05/27/us-court-to-hear-merck-appeal-on-vioxx-investor-suit/"", ""snippet"": ""The U.S. Supreme Court said on Tuesday that it would hear an appeal by Merck of a ruling that reinstated a securities fraud lawsuit involving the company\u2019s disclosures to investors about its withdrawn Vioxx pain drug."", ""lead_paragraph"": ""The Supreme Court said on Tuesday that it would hear an appeal by Merck of a ruling that reinstated a securities fraud lawsuit involving the company\u2019s disclosures to investors about its withdrawn Vioxx pain drug."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""U.S. Court to Hear Merck Appeal on Vioxx Investor Suit"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-05-27T11:35:16+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/43c1ffb8-c3fe-59e6-b6b9-43eb86b23d46"", ""word_count"": 325, ""uri"": ""nyt://article/43c1ffb8-c3fe-59e6-b6b9-43eb86b23d46""}"
2009-06-04,"{""abstract"": ""Merck may be considering selling some veterinary medicine assets or the animal health business of Schering-Plough as it prepares to acquire the company."", ""web_url"": ""https://dealbook.nytimes.com/2009/06/04/merck-may-sell-animal-drug-assets-before-merger/"", ""snippet"": ""Merck may be considering selling some veterinary medicine assets or the animal health business of Schering-Plough as it prepares to acquire the company."", ""lead_paragraph"": ""Merck is considering selling some of its veterinary medicine assets or the animal health business of Schering-Plough, as it prepares to acquire its New Jersey neighbor, according to press reports."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck May Sell Animal Drug Assets Before Merger"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-06-04T11:36:56+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/5d7ad8cd-5ed6-51d5-9e17-75965c442fee"", ""word_count"": 335, ""uri"": ""nyt://article/5d7ad8cd-5ed6-51d5-9e17-75965c442fee""}"
2009-06-11,"{""abstract"": ""Merck, the pharmaceutical group, said Wednesday that 16,000 jobs would be lost as it combined operations with its rival Schering-Plough."", ""web_url"": ""https://dealbook.nytimes.com/2009/06/11/merck-to-shed-16000-jobs-as-it-buys-schering/"", ""snippet"": ""Merck, the pharmaceutical group, said Wednesday that 16,000 jobs would be lost as it combined operations with its rival Schering-Plough."", ""lead_paragraph"": ""Merck, the pharmaceutical group, said Wednesday that 16,000 jobs would be lost as it joined its operations with its rival Schering-Plough, the French daily La Tribune reported. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck to Shed 16,000 Jobs as It Buys Schering"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-06-11T11:13:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/af2c642e-f8f8-550a-8e80-f0ab929af71a"", ""word_count"": 77, ""uri"": ""nyt://article/af2c642e-f8f8-550a-8e80-f0ab929af71a""}"
2009-07-30,"{""abstract"": ""Sanofi-Aventis and Merck announced Thursday that the two companies had agreed for Merck to sell its stake in their animal-health joint venture Merial for $4 billion in cash."", ""web_url"": ""https://dealbook.nytimes.com/2009/07/30/sanofi-and-merck-announce-4-billion-merial-sale/"", ""snippet"": ""Sanofi-Aventis and Merck announced Thursday that the two companies had agreed for Merck to sell its stake in their animal-health joint venture Merial for $4 billion in cash."", ""lead_paragraph"": ""Sanofi-Aventis said Thursday it had agreed to buy Merck & Company\u2019s 50 percent stake in Merial, an animal-health joint venture, for $4 billion in cash. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Sanofi and Merck Announce $4 Billion Merial Sale"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-07-30T08:21:07+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chris V. Nicholson"", ""person"": [{""firstname"": ""Chris"", ""middlename"": ""V."", ""lastname"": ""Nicholson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/29af40ff-b772-52dc-9720-08d064e84c85"", ""word_count"": 319, ""uri"": ""nyt://article/29af40ff-b772-52dc-9720-08d064e84c85""}"
2009-07-31,"{""abstract"": ""Merck is selling its Merial stake to clear a path for its merger with Schering-Plough, but it could create an even bigger joint venture with Sanofi after that deal wins approval."", ""web_url"": ""https://www.nytimes.com/2009/07/31/business/31drug.html"", ""snippet"": ""Merck is selling its Merial stake to clear a path for its merger with Schering-Plough, but it could create an even bigger joint venture with Sanofi after that deal wins approval."", ""lead_paragraph"": ""The drug giant Merck said Thursday it would sell its stake in a big animal-health joint venture for $4 billion \u0097 but with a side deal that could eventually let the company create an even bigger version of the same business. "", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Selling Stake in Animal Venture"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Selling Stake in Animal Venture"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sanofi-Aventis S.A"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2009-07-31T00:51:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1bd8a349-3c0f-5a9e-9525-0640d738ca31"", ""word_count"": 717, ""uri"": ""nyt://article/1bd8a349-3c0f-5a9e-9525-0640d738ca31""}"
2009-08-05,"{""abstract"": ""Merck and Schering-Plough said that they would pay $41.5 million to settle suits claiming they delayed study results on their cholesterol drug Vytorin because the data was unfavorable."", ""web_url"": ""https://www.nytimes.com/2009/08/06/business/06drug.html"", ""snippet"": ""Merck and Schering-Plough said that they would pay $41.5 million to settle suits claiming they delayed study results on their cholesterol drug Vytorin because the data was unfavorable."", ""lead_paragraph"": ""Merck and Schering-Plough agreed Wednesday to pay $41.5 million to settle class-action lawsuits that accused them of withholding unfavorable results of a clinical trial of the cholesterol drugs Vytorin and Zetia."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Schering and Merck Are Settling Vytorin Suits"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Schering and Merck to Settle Cholesterol Drug Lawsuits"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Schering Plough Corp"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vytorin (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2009-08-05T14:32:52+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Gerry Shih"", ""person"": [{""firstname"": ""Gerry"", ""middlename"": null, ""lastname"": ""Shih"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b7d7da29-afed-50f2-afcc-99d42a46dd65"", ""word_count"": 287, ""uri"": ""nyt://article/b7d7da29-afed-50f2-afcc-99d42a46dd65""}"
2009-09-03,"{""abstract"": ""Merck spent $7 million in the second quarter to defend itself in the first of at least 900 pending cases in which plaintiffs claim that taking Fosamax caused jaw injuries."", ""web_url"": ""https://www.nytimes.com/2009/09/03/business/03drug.html"", ""snippet"": ""Merck spent $7 million in the second quarter to defend itself in the first of at least 900 pending cases in which plaintiffs claim that taking Fosamax caused jaw injuries."", ""lead_paragraph"": ""Drug executives, product liability lawyers and Wall Street analysts are closely watching a jury trial in New York over medical problems associated with Fosamax, a drug from Merck that has been taken by millions of women to offset the bone loss associated with menopause. "", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""High Stakes for Merck in Litigation on Fosamax"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""High Stakes For Merck In Litigation On Fosamax"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Keenan, John F"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Liability for Products"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2009-09-03T01:56:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a30d672a-d1ad-5a62-bfac-261707b4256d"", ""word_count"": 1265, ""uri"": ""nyt://article/a30d672a-d1ad-5a62-bfac-261707b4256d""}"
2009-09-10,"[{""abstract"": ""Merck and GlaxoSmithKline, with the support of federal panels, plan to expand use of their treatments against the human papillomavirus."", ""web_url"": ""https://www.nytimes.com/2009/09/10/business/10drug.html"", ""snippet"": ""Merck and GlaxoSmithKline, with the support of federal panels, plan to expand use of their treatments against the human papillomavirus."", ""lead_paragraph"": ""Two pharmaceutical giants are vying for the billions of dollars up for grabs in the market for vaccines against the human papillomavirus, or HPV, a sexually transmitted infection that can cause cervical cancer and genital warts."", ""print_section"": ""B"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Two Giants Vie for Billions in S.T.D. Vaccine Market"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Two Giants Vie for Billions In S.T.D. Vaccine Market"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cervarix (Vaccine)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Gardasil (Vaccine)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Human Papilloma Virus (HPV)"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2009-09-10T00:49:32+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f4a4f290-7e20-516a-ae25-aed67f7b9210"", ""word_count"": 917, ""uri"": ""nyt://article/f4a4f290-7e20-516a-ae25-aed67f7b9210""}, {""abstract"": ""The AIDS Treatment Activists Coalition, representing 21 groups, gave an overall rating of C-minus to the pharmaceutical industry."", ""web_url"": ""https://www.nytimes.com/2009/09/10/business/10aids.html"", ""snippet"": ""The AIDS Treatment Activists Coalition, representing 21 groups, gave an overall rating of C-minus to the pharmaceutical industry."", ""lead_paragraph"": "" Merck won the highest grade and Abbott Laboratories flunked in a report card being issued Thursday by a prominent group of AIDS treatment activists after a yearlong study of the actions of nine major pharmaceutical companies to address the contagion in the United States."", ""print_section"": ""B"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""AIDS Activists Issue Grades to Drug Companies"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""AIDS Activists Issue Grades to Drug Companies"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Abbott Laboratories"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Acquired Immune Deficiency Syndrome"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2009-09-10T04:02:43+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a5d46f98-1488-5443-af4c-f976a6c2f05e"", ""word_count"": 719, ""uri"": ""nyt://article/a5d46f98-1488-5443-af4c-f976a6c2f05e""}]"
2009-09-12,"{""abstract"": ""Jurors sent the judge desperate hand-scrawled notes saying they were deadlocked over a verdict in the trial, which had been monitored as a bellwether for hundreds of other similar lawsuits against Merck."", ""web_url"": ""https://www.nytimes.com/2009/09/12/business/12drug.html"", ""snippet"": ""Jurors sent the judge desperate hand-scrawled notes saying they were deadlocked over a verdict in the trial, which had been monitored as a bellwether for hundreds of other similar lawsuits against Merck."", ""lead_paragraph"": ""A federal judge in the first jury trial involving the bone drug Fosamax declared a mistrial on Friday after jurors started sending him desperate hand-scrawled notes saying they were deadlocked over a verdict. "", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/09/12/business/12drugA-xlP.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2009/09/12/business/12drugA-xlP.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/09/12/business/12drugA-75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/09/12/business/12drugA-75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Jury Deadlock Ends a Trial Over Merck\u2019s Bone Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Jury Deadlock Ends a Trial Over Merck\u2019s Bone Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Keenan, John F"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Bones"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Jaw (Body Part)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Fosamax (Drug)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Decisions and Verdicts"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2009-09-12T01:26:59+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/24af0f27-c17d-51f9-80bd-0086858fa23c"", ""word_count"": 770, ""uri"": ""nyt://article/24af0f27-c17d-51f9-80bd-0086858fa23c""}"
2009-10-26,"{""abstract"": ""European antitrust regulators have given their blessing to the $41 billion merger of healthcare giants Merck and Schering-Plough."", ""web_url"": ""https://dealbook.nytimes.com/2009/10/26/eu-regulators-ok-merck-schering-deal/"", ""snippet"": ""European antitrust regulators have given their blessing to the $41 billion merger of healthcare giants Merck and Schering-Plough."", ""lead_paragraph"": ""European antitrust regulators have given their blessing to the $41 billion merger of healthcare giants Merck and Schering-Plough."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""E.U. Regulators Approve Merck-Schering Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-10-26T11:47:49+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/4537a7c5-2c3d-542b-8dfa-c2b5b7be3a63"", ""word_count"": 80, ""uri"": ""nyt://article/4537a7c5-2c3d-542b-8dfa-c2b5b7be3a63""}"
2009-10-30,"{""abstract"": ""Merck and Schering-Plough said Thursday they have won merger approval from the Federal Trade Commission and antitrust regulators in Switzerland and Canada."", ""web_url"": ""https://dealbook.nytimes.com/2009/10/30/merck-merger-wins-ftc-approval/"", ""snippet"": ""Merck and Schering-Plough said Thursday they have won merger approval from the Federal Trade Commission and antitrust regulators in Switzerland and Canada."", ""lead_paragraph"": ""Merck and Schering-Plough said Thursday they have won merger approval from the Federal Trade Commission and antitrust regulators in Switzerland and Canada."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Merger Wins F.T.C. Approval"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-10-30T10:27:48+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/c4cee699-2e95-5ef0-bd86-6225aefd264a"", ""word_count"": 199, ""uri"": ""nyt://article/c4cee699-2e95-5ef0-bd86-6225aefd264a""}"
2009-11-13,"{""abstract"": ""Researchers will present results with potentially significant implications for multibillion-dollar cholesterol medications from Merck."", ""web_url"": ""https://www.nytimes.com/2009/11/13/health/research/13drug.html"", ""snippet"": ""Researchers will present results with potentially significant implications for multibillion-dollar cholesterol medications from Merck."", ""lead_paragraph"": ""Some of Wall Street\u2019s leading drug industry analysts are scheduled to fly to Orlando, Fla., on Sunday afternoon. A junket to SeaWorld it is not."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""A New Cholesterol Study Puts Focus on Merck Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Cholesterol Study Rivets An Industry"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2009-11-13T01:59:49+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""subsection_name"": ""Research"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8a7c7d10-1d56-52af-80d5-f77e8ac1298c"", ""word_count"": 970, ""uri"": ""nyt://article/8a7c7d10-1d56-52af-80d5-f77e8ac1298c""}"
2009-11-16,"{""abstract"": ""Critics say the industry is trying to establish a higher price base before Congress passes legislation that tries to curb drug spending in coming years."", ""web_url"": ""https://www.nytimes.com/2009/11/16/business/16drugprices.html"", ""snippet"": ""Critics say the industry is trying to establish a higher price base before Congress passes legislation that tries to curb drug spending in coming years."", ""lead_paragraph"": ""Even as drug makers promise to support Washington\u2019s health care overhaul by shaving $8 billion a year off the nation\u2019s drug costs after the legislation takes effect, the industry has been raising its prices at the fastest rate in years."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/11/16/business/16drugprices_CA0/thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/11/16/business/16drugprices_CA0/thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Drug Makers Raise Prices in Face of Health Care Reform"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""DRUG COMPANIES INCREASE PRICES IN FACE OF CHANGE"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Reform and Reorganization"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AARP"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prices (Fares, Fees and Rates)"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2009-11-16T02:39:29+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/60d66b64-2b05-5782-a452-78f9d3f4988c"", ""word_count"": 1316, ""uri"": ""nyt://article/60d66b64-2b05-5782-a452-78f9d3f4988c""}"
2009-11-17,"{""abstract"": ""The results of the long-awaited trial could have been worse for Zetia, the blockbuster cholesterol-lowering drug, analysts said, and the drug maker\u2019s shares rose."", ""web_url"": ""https://www.nytimes.com/2009/11/17/business/17drug.html"", ""snippet"": ""The results of the long-awaited trial could have been worse for Zetia, the blockbuster cholesterol-lowering drug, analysts said, and the drug maker\u2019s shares rose."", ""lead_paragraph"": ""ORLANDO, Fla. \u0097 Such are the fortunes of the Merck cholesterol drug Zetia that a study reporting a lack of medical benefit is considered good news for investors."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/11/17/business/17drug_CA0/thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/11/17/business/17drug_CA0/thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Investors Seem Unshaken After Study of Merck Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Investors Seem Unshaken After Study of Merck Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Tests and Testing"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zetia (Drug)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMERICAN HEART ASSN"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2009-11-17T02:02:31+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/5650b735-4da6-579e-a489-b5264b01ba23"", ""word_count"": 922, ""uri"": ""nyt://article/5650b735-4da6-579e-a489-b5264b01ba23""}"
2009-11-24,"{""abstract"": ""A study proposes a broad model for monitoring drug safety that would consist of detailed publicly available data that independent researchers could freely analyze."", ""web_url"": ""https://www.nytimes.com/2009/11/24/health/24vioxx.html"", ""snippet"": ""A study proposes a broad model for monitoring drug safety that would consist of detailed publicly available data that independent researchers could freely analyze."", ""lead_paragraph"": ""What could be done to prevent another Vioxx? This pain medication for arthritis became a blockbuster after its introduction in 1999, only to be taken off the market in 2004 when a study linked the drug to an increased risk of heart attack and strokes. "", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Public Database Is Urged to Monitor Drug Safety"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Public Database Is Urged To Monitor Drug Safety"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Accidents and Safety"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2009-11-24T02:56:55+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ed81e2fa-1b20-5da2-91b3-f024b2f24c76"", ""word_count"": 1140, ""uri"": ""nyt://article/ed81e2fa-1b20-5da2-91b3-f024b2f24c76""}"
2010-02-17,"[{""abstract"": ""Merck posted quarterly revenue above analysts\u2019 estimates on Tuesday, helped by strong sales of its diabetes and allergy drugs, Reuters reported."", ""web_url"": ""https://dealbook.nytimes.com/2010/02/17/in-wake-of-merger-merck-beats-forecasts/"", ""snippet"": ""Merck posted quarterly revenue above analysts\u2019 estimates on Tuesday, helped by strong sales of its diabetes and allergy drugs, Reuters reported."", ""lead_paragraph"": ""Merck posted quarterly revenue above analysts\u2019 estimates on Tuesday, helped by strong sales of its diabetes and allergy drugs, Reuters reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""In Wake of Merger, Merck Beats Forecasts"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol-Myers Squibb Co"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-02-17T09:56:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/2905d6ef-1339-5073-9fd9-192a48d86d7d"", ""word_count"": 293, ""uri"": ""nyt://article/2905d6ef-1339-5073-9fd9-192a48d86d7d""}, {""abstract"": ""Stocks posted their biggest daily percentage gain in three months on Tuesday after strong revenue from Merck and positive regional manufacturing data instilled confidence in the economic outlook, Reuters reported."", ""web_url"": ""https://dealbook.nytimes.com/2010/02/17/wall-street-returns-closing-higher/"", ""snippet"": ""Stocks posted their biggest daily percentage gain in three months on Tuesday after strong revenue from Merck and positive regional manufacturing data instilled confidence in the economic outlook, Reuters reported."", ""lead_paragraph"": ""Stocks posted their biggest daily percentage gain in three months on Tuesday after strong revenue from the drug maker Merck and positive regional manufacturing data instilled confidence in the economic outlook."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Shares Gain as Merck Reports Strong Results"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Barclays PLC"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Chevron Corp"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""General Growth Properties"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Georgia Power Company"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Intel Corp"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Southern Co"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-02-17T10:33:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/0579c42b-1d28-57b4-8bba-693cd4a10655"", ""word_count"": 496, ""uri"": ""nyt://article/0579c42b-1d28-57b4-8bba-693cd4a10655""}]"
2010-03-01,"[{""abstract"": ""Merck of Germany said on Sunday that it had agreed to buy Millipore, an American provider of tools and services for bioscience companies, for about $7.2 billion, including debt."", ""web_url"": ""https://dealbook.nytimes.com/2010/02/28/germanys-merck-to-buy-millipore-for-7-2-billion/"", ""snippet"": ""Merck of Germany said on Sunday that it had agreed to buy Millipore, an American provider of tools and services for bioscience companies, for about $7.2 billion, including debt."", ""lead_paragraph"": ""Merck of Germany said on Sunday that it had agreed to buy Millipore, an American provider of purifiers and filters for biotechnology laboratories, for about $7.2 billion, including debt."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Germany\u2019s Merck to Buy Millipore for $7.2 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck of Germany"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Millipore Corp"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2010-03-01T00:38:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/d01b18af-eae4-5c1e-a7cf-7f5c0fdb65df"", ""word_count"": 300, ""uri"": ""nyt://article/d01b18af-eae4-5c1e-a7cf-7f5c0fdb65df""}, {""abstract"": ""The takeover of Millipore, a provider of purifiers and filters for laboratories, will give Merck a big presence in products for the biotechnology industry."", ""web_url"": ""https://www.nytimes.com/2010/03/01/business/01merck.html"", ""snippet"": ""The takeover of Millipore, a provider of purifiers and filters for laboratories, will give Merck a big presence in products for the biotechnology industry."", ""lead_paragraph"": ""Merck of Germany said on Sunday that it had agreed to buy Millipore, an American provider of purifiers and filters for biotechnology laboratories, for about $7.2 billion, including debt."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck to Pay $7.2 Billion for Millipore"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck to Pay $7.2 Billion For Millipore"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck of Germany"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Millipore Corp"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Biotechnology"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-03-01T02:28:04+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1226c403-18ce-5fca-ad0c-06ee3c4d8029"", ""word_count"": 275, ""uri"": ""nyt://article/1226c403-18ce-5fca-ad0c-06ee3c4d8029""}]"
2010-03-06,"{""abstract"": ""Merck\u2019s Australian unit failed to warn a doctor about heart risks associated with its painkiller Vioxx, a court in Melbourne found. "", ""web_url"": ""https://www.nytimes.com/2010/03/06/business/06bizbriefs-AUSTRALIANCO_BRF.html"", ""snippet"": ""Merck\u2019s Australian unit failed to warn a doctor about heart risks associated with its painkiller Vioxx, a court in Melbourne found. "", ""lead_paragraph"": ""Merck\u2019s Australian unit failed to warn a doctor about heart risks associated with its painkiller Vioxx, a court in Melbourne found, and might be ordered to pay almost 290,000 Australian dollars ($261,000) in damages. The Federal Court awarded the amount to Graeme R. Peterson, 59, in a case against Merck Sharpe & Dohme (Australia), the plaintiff\u2019s law firm, Slater & Gordon, said Friday. The court found that Vioxx contributed to Mr. Peterson\u2019s heart attack in 2003, according to the judgment. Merck said in a statement that it would appeal. Merck, based in Whitehouse Station, N.J., withdrew Vioxx in 2004 after a study showed it doubled the risk of heart attacks and strokes. "", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Australian Court Finds Damages in a Vioxx Case"", ""kicker"": ""Business Briefing | Legal"", ""content_kicker"": null, ""print_headline"": ""Australian Court Finds Damages In a Vioxx Case"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""glocations"", ""value"": ""Australia"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2010-03-06T03:59:20+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Brief"", ""_id"": ""nyt://article/414cfd68-95d0-5656-ad72-1435776f9d3f"", ""word_count"": 115, ""uri"": ""nyt://article/414cfd68-95d0-5656-ad72-1435776f9d3f""}"
2010-03-09,"{""abstract"": ""Merck and Sanofi-Aventis, two of the world\u2019s biggest pharmaceutical companies, said Tuesday they are uniting their animal health businesses in a deal to lead in the veterinary industry, The Associated Press reported."", ""web_url"": ""https://dealbook.nytimes.com/2010/03/09/sanofi-and-merck-announce-animal-health-venture/"", ""snippet"": ""Merck and Sanofi-Aventis, two of the world\u2019s biggest pharmaceutical companies, said Tuesday they are uniting their animal health businesses in a deal to lead in the veterinary industry, The Associated Press reported."", ""lead_paragraph"": ""Two of the world\u2019s biggest pharmaceutical companies said Tuesday they are uniting their animal health businesses in a deal to become the top dog in the veterinary industry, The Associated Press reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Sanofi and Merck Announce Animal Health Venture"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Sanofi-Aventis SA"", ""rank"": 1, ""major"": ""N""}], ""pub_date"": ""2010-03-09T09:11:40+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chris V. Nicholson"", ""person"": [{""firstname"": ""Chris"", ""middlename"": ""V."", ""lastname"": ""Nicholson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/285456d8-5100-5c91-a66e-175c34f3bebd"", ""word_count"": 178, ""uri"": ""nyt://article/285456d8-5100-5c91-a66e-175c34f3bebd""}"
2010-04-03,"{""abstract"": ""Can a settlement in a Merck shareholder case provide a road map toward the future of corporate governance?"", ""web_url"": ""https://www.nytimes.com/2010/04/04/business/04stream.html"", ""snippet"": ""Can a settlement in a Merck shareholder case provide a road map toward the future of corporate governance?"", ""lead_paragraph"": ""SHAREHOLDERS of Merck sued in 2004, contending that current and former company officers and directors had breached their fiduciary duties in the marketing of the painkiller Vioxx, causing investors to lose billions. "", ""print_section"": ""BU"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Does Merck Agreement Pave a Road Toward Change?"", ""kicker"": ""Slipstream"", ""content_kicker"": null, ""print_headline"": ""A Road To Change, Or Window Dressing?"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporations"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Ethics"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executives and Management"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2010-04-03T22:24:05+0000"", ""document_type"": ""article"", ""news_desk"": ""SundayBusiness"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8d9e537e-8f44-5cd1-bd89-2b0852f67f5f"", ""word_count"": 1164, ""uri"": ""nyt://article/8d9e537e-8f44-5cd1-bd89-2b0852f67f5f""}"
2010-04-04,"{""abstract"": ""The settlement by Merck of a shareholder lawsuit over Vioxx represent what may turn out to be a pivotal moment in the corporate governance arena."", ""web_url"": ""https://dealbook.nytimes.com/2010/04/04/does-merck-agreement-pave-a-road-toward-change/"", ""snippet"": ""The settlement by Merck of a shareholder lawsuit over Vioxx represent what may turn out to be a pivotal moment in the corporate governance arena."", ""lead_paragraph"": ""Shareholders of Merck sued in 2004, contending that current and former company officers and directors had breached their fiduciary duties in the marketing of the painkiller Vioxx, causing investors to lose billions."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Does Merck Agreement Pave a Road Toward Change?"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Boards of Directors"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executives and Management"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-04-04T18:27:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/7a0fba06-b7c0-51ed-9bd4-f0cd0a60d541"", ""word_count"": 1145, ""uri"": ""nyt://article/7a0fba06-b7c0-51ed-9bd4-f0cd0a60d541""}"
2010-06-14,"{""abstract"": ""The Human Genome Project has not produced the promised cornucopia of new drugs."", ""web_url"": ""https://www.nytimes.com/2010/06/15/business/15genome.html"", ""snippet"": ""The Human Genome Project has not produced the promised cornucopia of new drugs."", ""lead_paragraph"": ""NORTH WALES, Pa. \u0097 At Merck\u2019s \u201cautomated biotechnology facility\u201d here, robot arms adapted from automobile factories deftly shuttle plates containing human cells. "", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/06/15/business/15genome-ready/15genome-ready-articleLarge.jpg"", ""height"": 335, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2010/06/15/business/15genome-ready/15genome-ready-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 335}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/06/15/business/15genome-ready/15genome-ready-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/06/15/business/15genome-ready/15genome-ready-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Awaiting the Genome Payoff"", ""kicker"": ""The Genome at 10"", ""content_kicker"": null, ""print_headline"": ""Awaiting the Genome Payoff"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""HUMAN GENOME PROJECT"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Genetics and Heredity"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""DNA (Deoxyribonucleic Acid)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2010-06-14T21:56:23+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/53e6384b-0854-5bfa-84d5-5e440d3026f5"", ""word_count"": 1358, ""uri"": ""nyt://article/53e6384b-0854-5bfa-84d5-5e440d3026f5""}"
2010-06-26,"{""abstract"": ""Merck lost a second trial to reach a verdict over claims that its osteoporosis drug Fosamax caused so-called jaw death."", ""web_url"": ""https://www.nytimes.com/2010/06/26/business/26bizbriefs-JURYSAYSMERC_BRF.html"", ""snippet"": ""Merck lost a second trial to reach a verdict over claims that its osteoporosis drug Fosamax caused so-called jaw death."", ""lead_paragraph"": ""Merck lost a second trial to reach a verdict over claims that its osteoporosis drug Fosamax caused so-called jaw death. The jury in New York set damages at $8 million in the case of Shirley Boles, 72, of Fort Walton Beach, Fla., who said she developed osteonecrosis of the jaw by taking Fosamax. With osteonecrosis, a bone is no longer alive and cannot regenerate because of a lack of blood supply, according to the National Osteonecrosis Foundation\u2019s Web site. The first Fosamax case resulted in a Merck victory in May. United States District Judge John F. Keenan, who is overseeing federal Fosamax litigation, scheduled three bellwether trials that might point the way to out-of-court settlements and show each side the other\u2019s strategy. The third case is to be tried in November. \u201cWe believe the jury verdict was a result of plaintiff\u2019s counsel\u2019s inflammatory and prejudicial remarks,\u201d Paul F. Strain, a lawyer for Merck, said in a statement. "", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Jury Says Merck Must Pay $8 Million in Fosamax Case"", ""kicker"": ""Business Briefing | Legal News"", ""content_kicker"": null, ""print_headline"": ""Jury Says Merck Must Pay $8 Million In Fosamax Case"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Fosamax (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2010-06-26T03:26:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Brief"", ""_id"": ""nyt://article/d2cbf536-c53b-5140-8389-f48000114048"", ""word_count"": 157, ""uri"": ""nyt://article/d2cbf536-c53b-5140-8389-f48000114048""}"
2010-07-09,"{""abstract"": ""The restructuring follows a merger of the drug giants Merck and Schering-Plough, and involves closing eight research and eight manufacturing sites worldwide."", ""web_url"": ""https://www.nytimes.com/2010/07/09/health/09merck.html"", ""snippet"": ""The restructuring follows a merger of the drug giants Merck and Schering-Plough, and involves closing eight research and eight manufacturing sites worldwide."", ""lead_paragraph"": ""The $41 billion merger last year of the drug giants Merck and Schering-Plough has a human cost for pharmaceutical industry employees."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Plans to Lay Off About 15% of Workers"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Plans to Lay Off About 15% of Workers"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Layoffs and Job Reductions"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Factories and Manufacturing"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-07-09T00:41:27+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/580e5bc4-18b4-5ca4-acb5-d36f275999f2"", ""word_count"": 440, ""uri"": ""nyt://article/580e5bc4-18b4-5ca4-acb5-d36f275999f2""}"
2010-07-22,"[{""abstract"": ""The late-trial success of telaprevir has given medical experts reason to believe a new wave of drugs could lead to far better treatment outcomes for patients who have the virus."", ""web_url"": ""https://www.nytimes.com/2010/07/22/business/22hepatitis.html"", ""snippet"": ""The late-trial success of telaprevir has given medical experts reason to believe a new wave of drugs could lead to far better treatment outcomes for patients who have the virus."", ""lead_paragraph"": "" New medicines are being developed that are expected to transform the care of patients with hepatitis C, making treatment far more effective and far less grueling."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/07/22/business/22hepatitis1/22hepatitis1-articleLarge.jpg"", ""height"": 330, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2010/07/22/business/22hepatitis1/22hepatitis1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 330}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/07/22/business/22hepatitis1/22hepatitis1-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/07/22/business/22hepatitis1/22hepatitis1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/07/22/business/22hepatitis1/22hepatitis1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Hope Against Hepatitis C"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Hope Against Hepatitis C"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Vertex Pharmaceuticals Incorporated"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hepatitis"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-07-22T00:02:20+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/0158e5da-87ab-5828-9b47-501b6e20d146"", ""word_count"": 1407, ""uri"": ""nyt://article/0158e5da-87ab-5828-9b47-501b6e20d146""}, {""abstract"": ""A little more than a year after acquiring Genentech, Roche said Thursday that its profits for the first half of this year had risen by 37 percent from the same period a year before as exceptional costs associated with the merger had fallen."", ""web_url"": ""https://dealbook.nytimes.com/2010/07/22/roche-profit-up-on-genentech-synergies/"", ""snippet"": ""A little more than a year after acquiring Genentech, Roche said Thursday that its profits for the first half of this year had risen by 37 percent from the same period a year before as exceptional costs associated with the merger had fallen."", ""lead_paragraph"": ""A little more than a year after acquiring Genentech, Roche said Thursday that its profits for the first half of this year had risen by 37 percent from the same period a year before as exceptional costs associated with the merger had fallen."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Roche Profit Up on Genentech Synergies"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Schwan, Severin"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Genentech Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""San Francisco (Calif)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Switzerland"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2010-07-22T08:34:25+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chris V. Nicholson"", ""person"": [{""firstname"": ""Chris"", ""middlename"": ""V."", ""lastname"": ""Nicholson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/d3bbca8e-689d-5f68-8066-894ff8837a73"", ""word_count"": 232, ""uri"": ""nyt://article/d3bbca8e-689d-5f68-8066-894ff8837a73""}]"
2010-08-05,"{""abstract"": ""New drugs for hepatitis C and superhigh cholesterol succeeded in late-stage clinical trials, the developers of the products announced on Wednesday."", ""web_url"": ""https://www.nytimes.com/2010/08/05/health/05drug.html"", ""snippet"": ""New drugs for hepatitis C and superhigh cholesterol succeeded in late-stage clinical trials, the developers of the products announced on Wednesday."", ""lead_paragraph"": ""New drugs for hepatitis C and superhigh cholesterol succeeded in late-stage clinical trials, the developers of the products announced on Wednesday. But both drugs have side effects that could dampen sales, analysts said."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Promising Results Reported for Cholesterol and Hepatitis C Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Promising Results Reported for Cholesterol and Hepatitis C Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Vertex Pharmaceuticals Incorporated"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hepatitis"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Isis Pharmaceuticals Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Genzyme Corp"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-08-05T00:26:28+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d81bfdcf-038c-5ec3-8003-b71b9b33d02a"", ""word_count"": 621, ""uri"": ""nyt://article/d81bfdcf-038c-5ec3-8003-b71b9b33d02a""}"
2010-08-14,"{""abstract"": ""The inquiry focuses on whether companies made illegal payments to doctors and officials in foreign countries."", ""web_url"": ""https://www.nytimes.com/2010/08/14/health/policy/14drug.html"", ""snippet"": ""The inquiry focuses on whether companies made illegal payments to doctors and officials in foreign countries."", ""lead_paragraph"": ""At least a dozen major drug and device makers are under investigation by federal prosecutors and securities regulators in a broadening bribery inquiry into whether the companies made illegal payments to doctors and health officials in foreign countries."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/08/14/business/drug/drug-jumbo.jpg"", ""height"": 689, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}], ""headline"": {""main"": ""U.S. Inquiry of Drug Makers Is Widened"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""U.S. Inquiry Of Drug Makers Is Widened"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Bribery and Kickbacks"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Breuer, Lanny A"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Health and Human Services Department"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2010-08-14T01:26:22+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""subsection_name"": ""Money & Policy"", ""byline"": {""original"": ""By Gardiner Harris and Natasha Singer"", ""person"": [{""firstname"": ""Gardiner"", ""middlename"": null, ""lastname"": ""Harris"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2609665c-b2ea-572a-9d81-a62246e46b9f"", ""word_count"": 1193, ""uri"": ""nyt://article/2609665c-b2ea-572a-9d81-a62246e46b9f""}"
2010-10-30,"{""abstract"": ""The drug maker exceeded analysts\u2019 third-quarter estimates by 2 cents."", ""web_url"": ""https://www.nytimes.com/2010/10/30/business/30merck.html"", ""snippet"": ""The drug maker exceeded analysts\u2019 third-quarter estimates by 2 cents."", ""lead_paragraph"": ""The drug maker Merck reported third-quarter profit on Friday that rose more than analysts had estimated, as reduced costs helped overcome revenue losses from drugs facing generic competition."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Cost Cuts Help Merck to Avert Revenue Losses"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""BUSINESS BRIEFING | MEDICINE; Merck\u2019s Profit Was Better Than Expected"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-10-30T02:30:12+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ac7368df-b914-5a30-a460-d3790db9b3d1"", ""word_count"": 270, ""uri"": ""nyt://article/ac7368df-b914-5a30-a460-d3790db9b3d1""}"
2010-11-11,"{""abstract"": ""As recent lawsuits suggest a long-term risk, doctors and drug makers are debating the use of osteoporosis drugs."", ""web_url"": ""https://www.nytimes.com/2010/11/11/health/11bone.html"", ""snippet"": ""As recent lawsuits suggest a long-term risk, doctors and drug makers are debating the use of osteoporosis drugs."", ""lead_paragraph"": ""Judith Graves, a 67-year-old retired investigator for the United States Army, developed a rare medical condition called jawbone death after taking Fosamax, a drug used by millions of American women with thinning bones."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/11/11/business/11BONE/11BONE-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/11/11/business/11BONE/11BONE-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/11/11/business/11BONE/11BONE-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Drug Suits Raise Questions for Doctors, and Juries"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Question for Doctors, and Juries"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Osteoporosis"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Bones"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Fosamax (Drug)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-11-11T00:26:28+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/83f3a8ed-6ab2-56d5-94e7-16cc76b10ca3"", ""word_count"": 1358, ""uri"": ""nyt://article/83f3a8ed-6ab2-56d5-94e7-16cc76b10ca3""}"
2010-11-17,"{""abstract"": ""Patients taking the drug anacetrapib had a 39.8 percent reduction in bad cholesterol and a 138.1 percent increase in good cholesterol."", ""web_url"": ""https://www.nytimes.com/2010/11/18/health/research/18merck.html"", ""snippet"": ""Patients taking the drug anacetrapib had a 39.8 percent reduction in bad cholesterol and a 138.1 percent increase in good cholesterol."", ""lead_paragraph"": ""Merck has a potential blockbuster in anacetrapib, an experimental cholesterol drug that increases HDL, or \u201cgood\u201d cholesterol even as it lowers LDL, the \u201cbad\u201d cholesterol."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Drug for Cutting Cholesterol Is Promising"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Drug For Cutting Cholesterol Is Promising"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2010-11-17T22:52:06+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""subsection_name"": ""Research"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/971caecd-4a2a-5ddf-aed2-e6535f8b467a"", ""word_count"": 682, ""uri"": ""nyt://article/971caecd-4a2a-5ddf-aed2-e6535f8b467a""}"
2010-11-20,"[{""abstract"": ""Judith Graves, a Florida woman, had sued the company, claiming that its osteoporosis drug, Fosamax, caused her jawbone to disintegrate."", ""web_url"": ""https://www.nytimes.com/2010/11/20/business/20fosamax.html"", ""snippet"": ""Judith Graves, a Florida woman, had sued the company, claiming that its osteoporosis drug, Fosamax, caused her jawbone to disintegrate."", ""lead_paragraph"": ""Merck on Friday won a signature jury trial against Judith Graves, a Florida woman who had sued the company and claimed that its osteoporosis drug, Fosamax, caused her jawbone to disintegrate."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/11/20/business/Fosamax/Fosamax-jumbo.jpg"", ""height"": 1024, ""width"": 768, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Merck Not at Fault in Fosamax Trial, Jurors Say"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""In Trial on Bone Loss, Jurors Say Merck Is Not at Fault"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Fosamax (Drug)"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2010-11-20T00:52:48+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cdf626c4-2ba0-57e7-8eee-420b6e005988"", ""word_count"": 483, ""uri"": ""nyt://article/cdf626c4-2ba0-57e7-8eee-420b6e005988""}, {""abstract"": ""Patients with chronic kidney disease who took Vytorin, a cholesterol-lowering pill, had one-sixth fewer heart attacks, strokes or operations to unblock their arteries than patients taking a placebo."", ""web_url"": ""https://www.nytimes.com/2010/11/21/health/research/21drug.html"", ""snippet"": ""Patients with chronic kidney disease who took Vytorin, a cholesterol-lowering pill, had one-sixth fewer heart attacks, strokes or operations to unblock their arteries than patients taking a placebo."", ""lead_paragraph"": ""Patients with chronic kidney disease who took Vytorin, a cholesterol-lowering pill, had one-sixth fewer heart attacks, strokes or operations to unblock their arteries than patients taking a placebo, according to the results of a study presented on Saturday."", ""print_section"": ""A"", ""print_page"": ""25"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Study Suggests a Cholesterol Pill Benefits Patients With Kidney Disease"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Study Suggests a Cholesterol Pill Benefits Patients With Kidney Disease"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vytorin (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Kidneys"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-11-20T20:13:41+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""subsection_name"": ""Research"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cb62287c-ffd9-5956-a6f3-6c8302ac0656"", ""word_count"": 535, ""uri"": ""nyt://article/cb62287c-ffd9-5956-a6f3-6c8302ac0656""}]"
2011-01-28,"{""abstract"": ""Mr. Horan led Merck as the company\u2019s portfolio of pharmaceuticals expanded, including a hepatitis B vaccine, new antibiotics and heart medications."", ""web_url"": ""https://www.nytimes.com/2011/01/28/business/28horan.html"", ""snippet"": ""Mr. Horan led Merck as the company\u2019s portfolio of pharmaceuticals expanded, including a hepatitis B vaccine, new antibiotics and heart medications."", ""lead_paragraph"": ""John Horan, who led Merck as it expanded its portfolio of pharmaceuticals and became the world\u2019s largest drug maker, died on Saturday in Princeton, N.J. He was 90 and lived in Sea Girt, N.J."", ""print_section"": ""B"", ""print_page"": ""15"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/01/28/business/HORAN-obit/HORAN-obit-jumbo.jpg"", ""height"": 1024, ""width"": 709, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/01/28/business/HORAN-obit/HORAN-obit-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2011/01/28/business/HORAN-obit/HORAN-obit-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""John Horan, Former Chief of Merck, Dies at 90"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""John Horan, 90; Led Growth of the Drug Maker Merck"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""New Jersey"", ""rank"": 3, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Staten Island (NYC)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Blindness"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executives and Management"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Deaths (Obituaries)"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2011-01-28T01:59:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Segal"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Segal"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Obituary (Obit)"", ""_id"": ""nyt://article/2574e769-23fb-5e76-8898-33464cc13d2a"", ""word_count"": 476, ""uri"": ""nyt://article/2574e769-23fb-5e76-8898-33464cc13d2a""}"
2011-03-23,"{""abstract"": ""The French pharmaceutical giant Sanofi-Aventis says it will issue $7 billion worth of notes to help finance its acquisition of the American biotechnology firm Genzyme."", ""web_url"": ""https://dealbook.nytimes.com/2011/03/23/sanofi-raising-7-billion-in-notes-to-fund-genzyme/"", ""snippet"": ""The French pharmaceutical giant Sanofi-Aventis says it will issue $7 billion worth of notes to help finance its acquisition of the American biotechnology firm Genzyme."", ""lead_paragraph"": ""The French pharmaceutical giant Sanofi-Aventis said on Wednesday that it was issuing $7 billion worth of notes to help finance its acquisition of the American biotechnology firm Genzyme, which it agreed to last month."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Sanofi Raising $7 Billion in Debt to Fund Genzyme Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Genzyme Corp"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2011-03-23T09:44:53+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chris V. Nicholson"", ""person"": [{""firstname"": ""Chris"", ""middlename"": ""V."", ""lastname"": ""Nicholson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/6bd3c87e-9327-5855-b09e-19bd4e3dc46a"", ""word_count"": 212, ""uri"": ""nyt://article/6bd3c87e-9327-5855-b09e-19bd4e3dc46a""}"
2011-05-13,"{""abstract"": ""Victrelis, from Merck, is the first of a new generation of drugs that promise to increase the cure rate while shortening the treatment time."", ""web_url"": ""https://www.nytimes.com/2011/05/14/business/14drug.html"", ""snippet"": ""Victrelis, from Merck, is the first of a new generation of drugs that promise to increase the cure rate while shortening the treatment time."", ""lead_paragraph"": ""The Food and Drug Administration approved on Friday the first of a new generation of hepatitis C drugs that promises to increase the cure rate while shortening the time required for treatment."", ""print_section"": ""B"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck\u2019s Hepatitis C Drug Wins F.D.A. Approval"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck\u2019s Hepatitis C Drug Wins F.D.A. Approval"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hepatitis"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2011-05-13T23:17:20+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/12afdde7-d2c8-5224-8ed5-d7318e192a1f"", ""word_count"": 741, ""uri"": ""nyt://article/12afdde7-d2c8-5224-8ed5-d7318e192a1f""}"
2011-05-23,"{""abstract"": ""The approval of a Vertex Pharmaceuticals drug sets off a marketing battle with Merck."", ""web_url"": ""https://www.nytimes.com/2011/05/24/business/24drug.html"", ""snippet"": ""The approval of a Vertex Pharmaceuticals drug sets off a marketing battle with Merck."", ""lead_paragraph"": ""Vertex Pharmaceuticals won regulatory approval on Monday for a new hepatitis C drug, setting off a marketing battle with Merck over new drugs that are expected to improve the cure rate of the disease and shorten the duration of treatment. "", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Second Drug Wins Approval For Treatment of Hepatitis C"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Second Drug Wins Approval For Treatment of Hepatitis C"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Vertex Pharmaceuticals Incorporated"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hepatitis"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2011-05-23T15:37:06+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c86f670b-6c71-544e-a523-f34b7117bb55"", ""word_count"": 736, ""uri"": ""nyt://article/c86f670b-6c71-544e-a523-f34b7117bb55""}"
2011-06-20,"{""abstract"": ""Some large corporations are pushing for a tax holiday to bring back offshore profits, but the economic benefits were limited the last time such a break was given."", ""web_url"": ""https://www.nytimes.com/2011/06/20/business/20tax.html"", ""snippet"": ""Some large corporations are pushing for a tax holiday to bring back offshore profits, but the economic benefits were limited the last time such a break was given."", ""lead_paragraph"": ""Some of the nation\u2019s largest corporations have amassed vast profits outside the country and are pressing Congress and the Obama administration for a tax break to bring the money home."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Companies Push for Tax Break on Foreign Cash"", ""kicker"": ""But Nobody Pays That"", ""content_kicker"": null, ""print_headline"": ""Companies Push For a Tax Break On Foreign Cash"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporations"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Credits, Deductions and Exemptions"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Economy"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Labor and Jobs"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2011-06-20T01:51:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Kocieniewski"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Kocieniewski"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c68df20b-3311-5ea0-b0af-38d1b0ed5b98"", ""word_count"": 1852, ""uri"": ""nyt://article/c68df20b-3311-5ea0-b0af-38d1b0ed5b98""}"
2011-09-10,"{""abstract"": ""The F.D.A. is expected to issue a revised label in November for bone-building drugs like Fosamax, Actonel and Boniva."", ""web_url"": ""https://www.nytimes.com/2011/09/10/business/fda-panels-back-sterner-language-on-bone-drugs.html"", ""snippet"": ""The F.D.A. is expected to issue a revised label in November for bone-building drugs like Fosamax, Actonel and Boniva."", ""lead_paragraph"": ""Two advisory panels to the Food and Drug Administration on Friday recommended increasing the cautionary language on the product labels of bone-building drugs taken by more than five million women in the United States."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/09/10/business/Drug/Drug-jumbo.jpg"", ""height"": 1024, ""width"": 893, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Stronger Cautions Backed on Bone Drugs for Women"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Stronger Cautions Backed On Bone Drugs for Women"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Osteoporosis"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Warner Chilcott Ltd"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Bones"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Labeling and Labels"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Fosamax (Drug)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2011-09-10T00:40:23+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/975e7565-bab4-5fee-9e47-2c46da504d91"", ""word_count"": 722, ""uri"": ""nyt://article/975e7565-bab4-5fee-9e47-2c46da504d91""}"
2011-11-21,"{""abstract"": ""The federal approval of Eylea came after years of research and a total $1.2 billion in losses."", ""web_url"": ""https://www.nytimes.com/2011/11/21/business/eylea-a-vision-drug-wins-long-sought-approval.html"", ""snippet"": ""The federal approval of Eylea came after years of research and a total $1.2 billion in losses."", ""lead_paragraph"": ""It has three Nobel Prize winners on its board. Its chairman, P. Roy Vagelos, is a pharmaceutical industry star who ran Merck during its heyday. Its chief scientist has written frequently cited biomedical papers. "", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Success Long in Coming for Eylea, a Vision Treatment"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Success Long in Coming For a Vision Treatment"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Eyes and Eyesight"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Regeneron Pharmaceuticals Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Macular Degeneration"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2011-11-21T01:33:51+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/db5c81fe-7d1e-552e-b293-f2fff8579ec0"", ""word_count"": 811, ""uri"": ""nyt://article/db5c81fe-7d1e-552e-b293-f2fff8579ec0""}"
2011-11-22,"{""abstract"": ""Merck has pleaded guilty to a criminal charge over the marketing and sales of the painkiller Vioxx."", ""web_url"": ""https://www.nytimes.com/2011/11/23/business/merck-agrees-to-pay-950-million-in-vioxx-case.html"", ""snippet"": ""Merck has pleaded guilty to a criminal charge over the marketing and sales of the painkiller Vioxx."", ""lead_paragraph"": ""Merck has agreed to pay $950 million and has pleaded guilty to a criminal charge over the marketing and sales of the painkiller Vioxx, the company and the Justice Department said Tuesday."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck to Pay $950 Million Over Vioxx"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck to Pay $950 Million Over Vioxx"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Fines (Penalties)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vioxx (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Justice Department"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2011-11-22T20:45:05+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e10ea41a-3163-593a-8b74-7a1d29dc2850"", ""word_count"": 515, ""uri"": ""nyt://article/e10ea41a-3163-593a-8b74-7a1d29dc2850""}"
2011-12-07,"{""abstract"": ""A pledge by Merck to invest $1.5 billion in research and development in China suggests that the pharmaceutical industry\u2019s center of gravity is shifting eastward."", ""web_url"": ""https://www.nytimes.com/2011/12/07/business/chinas-allure-in-drug-research.html"", ""snippet"": ""A pledge by Merck to invest $1.5 billion in research and development in China suggests that the pharmaceutical industry\u2019s center of gravity is shifting eastward."", ""lead_paragraph"": ""Drug research tends to follow spending. Take Merck\u2019s pledge on Tuesday to invest $1.5 billion in research and development in China over five years. Citizens of emerging economies are growing wealthier and living longer, while the fiscal health of their governments is robust. Merck\u2019s step suggests that the pharmaceutical industry\u2019s center of gravity is shifting eastward accordingly."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/12/07/business/VIEWS/VIEWS-articleLarge.jpg"", ""height"": 370, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2011/12/07/business/VIEWS/VIEWS-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 370}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/12/07/business/VIEWS/VIEWS-jumbo.jpg"", ""height"": 707, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}], ""headline"": {""main"": ""China\u2019s Allure in Drug Research"", ""kicker"": ""Reuters Breakingviews"", ""content_kicker"": null, ""print_headline"": ""China\u2019s Allure in Drug Research"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""European Central Bank"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Economic Conditions and Trends"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bank of England"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""European Sovereign Debt Crisis (2010- )"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""China"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2011-12-07T01:07:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran and George Hay"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""George"", ""middlename"": null, ""lastname"": ""Hay"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d092a14f-6659-5cbf-aa8d-f0e31402a742"", ""word_count"": 729, ""uri"": ""nyt://article/d092a14f-6659-5cbf-aa8d-f0e31402a742""}"
2012-02-01,"{""abstract"": ""With its concentration of pharmaceutical giants and academic powerhouses, the region could be a major center for life sciences businesses, developers say."", ""web_url"": ""https://www.nytimes.com/2012/02/01/realestate/commercial/life-sciences-development-rebounds-in-central-new-jersey.html"", ""snippet"": ""With its concentration of pharmaceutical giants and academic powerhouses, the region could be a major center for life sciences businesses, developers say."", ""lead_paragraph"": ""EAST WINDSOR, N.J. \u2014 With its concentration of pharmaceutical giants like Merck, Johnson & Johnson, Bristol-Myers Squibb and ImClone Systems, and academic powerhouses like Princeton and Rutgers, central New Jersey has long had the foundation to be a major center for life sciences businesses."", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/02/01/business/Bio1/Bio1-articleLarge.jpg"", ""height"": 330, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2012/02/01/business/Bio1/Bio1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 330}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/02/01/business/Bio1/Bio1-jumbo.jpg"", ""height"": 575, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/02/01/business/Bio1/Bio1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2012/02/01/business/Bio1/Bio1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Life Sciences Projects Revive in Central New Jersey"", ""kicker"": ""Square Feet"", ""content_kicker"": null, ""print_headline"": ""Life Sciences Projects Revive in Central New Jersey"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""ImClone Systems Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Princeton University"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novo Nordisk A/S"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Elementis"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 5, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""New Jersey"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Real Estate (Commercial)"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Area Planning and Renewal"", ""rank"": 9, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Biotechnology"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2012-02-01T02:17:15+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Real Estate"", ""subsection_name"": ""Commercial Real Estate"", ""byline"": {""original"": ""By Alison Gregor"", ""person"": [{""firstname"": ""Alison"", ""middlename"": null, ""lastname"": ""Gregor"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a9e9dac4-9e43-53db-b8ce-d1cece2006d1"", ""word_count"": 1031, ""uri"": ""nyt://article/a9e9dac4-9e43-53db-b8ce-d1cece2006d1""}"
2012-03-06,"{""abstract"": ""The proposed new drug would combine Merck\u2019s drug Zetia, which lowers \u201cbad\u201d cholesterol, with the generic version of Lipitor, the statin made by Pfizer."", ""web_url"": ""https://www.nytimes.com/2012/03/06/health/fda-rejects-mercks-application-for-combination-drug.html"", ""snippet"": ""The proposed new drug would combine Merck\u2019s drug Zetia, which lowers \u201cbad\u201d cholesterol, with the generic version of Lipitor, the statin made by Pfizer."", ""lead_paragraph"": ""The Food and Drug Administration on Monday rejected an application by Merck to combine a cholesterol-fighting pill with the generic version of Lipitor. "", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""In Rejection, F.D.A. Wants More Data From Merck"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""In Rejection, F.D.A Wants More Data From Merck"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Vytorin (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zetia (Drug)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2012-03-06T00:20:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d71b3f6b-d035-520e-837d-13469c24ef1e"", ""word_count"": 474, ""uri"": ""nyt://article/d71b3f6b-d035-520e-837d-13469c24ef1e""}"
2012-06-21,"{""abstract"": ""The health advocates contend Merck is improperly marketing the allergy medicine directly to children by using characters from the movie \u201cMadagascar 3: Europe\u2019s Most Wanted.\u201d"", ""web_url"": ""https://www.nytimes.com/2012/06/21/health/health-advocates-denounce-mercks-claritin-marketing.html"", ""snippet"": ""The health advocates contend Merck is improperly marketing the allergy medicine directly to children by using characters from the movie \u201cMadagascar 3: Europe\u2019s Most Wanted.\u201d"", ""lead_paragraph"": ""Public health advocates on Wednesday accused the drug company Merck of improperly marketing an over-the-counter allergy medicine directly to children using animated characters from the movie \u201cMadagascar 3: Europe\u2019s Most Wanted.\u201d "", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/06/21/business/Claritin/Claritin-jumbo.jpg"", ""height"": 1024, ""width"": 948, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/06/21/business/Claritin/Claritin-superJumbo.jpg"", ""height"": 2048, ""width"": 1896, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/06/21/business/Claritin/Claritin-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2012/06/21/business/Claritin/Claritin-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/06/21/business/Claritin/Claritin-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Health Groups Criticize Allergy Drug Promotion"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Health Groups Criticize Allergy Drug Promotion"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Claritin (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ANIMATED FILMS"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""creative_works"", ""value"": ""Madagascar 3 (Movie)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Children and Childhood"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Movies"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2012-06-21T01:53:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e5f14071-fb4c-55e2-b312-257dcd9bb507"", ""word_count"": 686, ""uri"": ""nyt://article/e5f14071-fb4c-55e2-b312-257dcd9bb507""}"
2012-12-20,"{""abstract"": ""The combination did not protect against heart attacks and strokes in a large clinical trial, and the company said it would no longer pursue its approval in the United States."", ""web_url"": ""https://www.nytimes.com/2012/12/21/business/merck-says-niacin-combination-drug-failed-in-trial.html"", ""snippet"": ""The combination did not protect against heart attacks and strokes in a large clinical trial, and the company said it would no longer pursue its approval in the United States."", ""lead_paragraph"": ""The drug maker Merck announced on Thursday that a combination of niacin and another medicine failed to protect against heart attacks and strokes in a large clinical trial, and that the company would no longer pursue approval of the combination drug in the United States."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Says Niacin Drug Has Failed Large Trial"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Says Niacin Drug Has Failed Large Trial"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Heart"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Niacin"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stroke"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2012-12-20T17:41:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/358c6cab-e3f3-5b8b-a0e8-da622edef8c4"", ""word_count"": 695, ""uri"": ""nyt://article/358c6cab-e3f3-5b8b-a0e8-da622edef8c4""}"
2013-02-01,"{""abstract"": ""The drug maker said it would delay seeking approval for an experimental osteoporosis drug, an announcement that helped send the company\u2019s shares down 3 percent."", ""web_url"": ""https://www.nytimes.com/2013/02/02/business/merck-delays-osteoporosis-drug.html"", ""snippet"": ""The drug maker said it would delay seeking approval for an experimental osteoporosis drug, an announcement that helped send the company\u2019s shares down 3 percent."", ""lead_paragraph"": ""Merck said on Friday that it would delay seeking approval for an experimental osteoporosis drug, an announcement that helped send the company\u2019s shares down 3 percent on the same day it announced its fourth-quarter earnings for 2012."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Delays Osteoporosis Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Delays Application for Osteoporosis Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Osteoporosis"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2013-02-01T19:34:28+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/031f048b-ff58-5287-b15a-2f388b3724fc"", ""word_count"": 370, ""uri"": ""nyt://article/031f048b-ff58-5287-b15a-2f388b3724fc""}"
2013-02-14,"{""abstract"": ""The drug maker agreed to pay $688 million to settle two lawsuits that said it had harmed investors by delaying the release of unfavorable study results for a cholesterol drug."", ""web_url"": ""https://www.nytimes.com/2013/02/15/business/merck-settles-investor-suits-over-cholesterol-drug.html"", ""snippet"": ""The drug maker agreed to pay $688 million to settle two lawsuits that said it had harmed investors by delaying the release of unfavorable study results for a cholesterol drug."", ""lead_paragraph"": ""Merck has agreed to pay $688 million to settle lawsuits claiming that it had harmed investors by delaying the release of unfavorable study results for its cholesterol drug Vytorin, the company announced on Thursday."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/15/business/subMerck/subMerck-articleLarge.jpg"", ""height"": 833, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/02/15/business/subMerck/subMerck-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 833}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/15/business/subMerck/subMerck-jumbo.jpg"", ""height"": 1024, ""width"": 738, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/15/business/subMerck/subMerck-superJumbo.jpg"", ""height"": 1157, ""width"": 833, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/15/business/subMerck/subMerck-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/02/15/business/subMerck/subMerck-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/15/business/subMerck/subMerck-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck Settles Suits Over Cholesterol Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Settles Suits Over Cholesterol Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vytorin (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Schering-Plough Corp"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Decisions and Verdicts"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zetia (Drug)"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2013-02-14T19:44:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/36e9a1f4-d67c-55c8-9c58-227739111696"", ""word_count"": 757, ""uri"": ""nyt://article/36e9a1f4-d67c-55c8-9c58-227739111696""}"
2013-03-07,"{""abstract"": ""Dr. Roger M. Perlmutter, the former research head of Amgen, will replace Peter S. Kim, who is retiring after a number of successes and some recent disappointments."", ""web_url"": ""https://www.nytimes.com/2013/03/08/business/merck-replaces-its-research-chief.html"", ""snippet"": ""Dr. Roger M. Perlmutter, the former research head of Amgen, will replace Peter S. Kim, who is retiring after a number of successes and some recent disappointments."", ""lead_paragraph"": ""Merck announced on Thursday that it was replacing its head of research with the retired research chief at Amgen, a leadership shake-up that follows several major setbacks in Merck\u2019s drug development pipeline."", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Replaces Its Research Chief"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Replaces Its Research Chief"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Appointments and Executive Changes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Kim, Peter S"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Perlmutter, Roger M"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2013-03-07T17:19:16+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e282edb7-f70c-592b-9c4a-46e97073b2b9"", ""word_count"": 553, ""uri"": ""nyt://article/e282edb7-f70c-592b-9c4a-46e97073b2b9""}"
2013-05-04,"{""abstract"": ""The drug pairs Merck\u2019s Zetia, which lowers low-density lipoprotein, with the generic version of Lipitor, the best-selling statin made by Pfizer that lost its patent protection in 2011."", ""web_url"": ""https://www.nytimes.com/2013/05/04/business/fda-approves-mercks-combination-drug-to-reduce-cholesterol.html"", ""snippet"": ""The drug pairs Merck\u2019s Zetia, which lowers low-density lipoprotein, with the generic version of Lipitor, the best-selling statin made by Pfizer that lost its patent protection in 2011."", ""lead_paragraph"": ""The Food and Drug Administration approved on Friday a combination drug developed by Merck that lowers a patient\u2019s cholesterol but has not been shown to reduce the risk of cardiovascular disease or death, the company said."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Drug to Cut Cholesterol Is Approved by the F.D.A."", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Drug to Cut Cholesterol Is Approved By the F.D.A."", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zetia (Drug)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2013-05-04T00:49:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/652e5389-f054-5e72-9f42-f3488c008e93"", ""word_count"": 474, ""uri"": ""nyt://article/652e5389-f054-5e72-9f42-f3488c008e93""}"
2013-05-16,"{""abstract"": ""Researchers reported that a combination of two drugs from Bristol-Myers Squibb appeared to shrink tumors in 41 percent of patients in a small study."", ""web_url"": ""https://www.nytimes.com/2013/05/16/business/melanoma-treatment-harnesses-immune-system-to-combat-cancer-cells.html"", ""snippet"": ""Researchers reported that a combination of two drugs from Bristol-Myers Squibb appeared to shrink tumors in 41 percent of patients in a small study."", ""lead_paragraph"": ""Cancer researchers are growing increasingly enthusiastic about harnessing the body\u2019s own immune system to fight tumors. And new research shows that two drugs that use this approach may be even better than one. "", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Melanoma Treatment Harnesses Immune System to Combat Cancer Cells"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Melanoma Treatment Harnesses Immune System to Combat Cancer Cells"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tumors"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Melanomas"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding A G"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 9, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Skin Cancer"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2013-05-16T01:01:31+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/31bd1774-50eb-543d-907c-1221a6eb3358"", ""word_count"": 678, ""uri"": ""nyt://article/31bd1774-50eb-543d-907c-1221a6eb3358""}"
2013-05-30,"{""abstract"": ""Findings by Dr. Peter C. Butler on Merck\u2019s medication Januvia are threatening the future of all drugs in its class, yearly sales of which exceed $9 billion."", ""web_url"": ""https://www.nytimes.com/2013/05/31/business/a-doctor-raises-questions-about-a-diabetes-drug.html"", ""snippet"": ""Findings by Dr. Peter C. Butler on Merck\u2019s medication Januvia are threatening the future of all drugs in its class, yearly sales of which exceed $9 billion."", ""lead_paragraph"": ""LOS ANGELES \u2014 Dr. Peter C. Butler initially declined a request by the drug maker Merck to test whether its new diabetes drug, Januvia, could help stave off the disease in rats."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/05/31/business/31diabetes/31diabetes-articleLarge.jpg"", ""height"": 411, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/05/31/business/31diabetes/31diabetes-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 411}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/05/31/business/31diabetes/31diabetes-jumbo.jpg"", ""height"": 701, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/05/31/business/31diabetes/31diabetes-superJumbo.jpg"", ""height"": 1402, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/05/31/business/31diabetes/31diabetes-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/05/31/business/31diabetes/31diabetes-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/05/31/business/31diabetes/31diabetes-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Lone Voice Raises Alarms on Lucrative Diabetes Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""A Lone Voice Raising Alarms"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack , Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Butler, Peter C"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Pancreatic Cancer"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Diabetes"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""European Medicines Agency"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2013-05-30T16:12:11+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ee4b9b9b-6d2a-5f95-b60e-3ebb9f401bdb"", ""word_count"": 1481, ""uri"": ""nyt://article/ee4b9b9b-6d2a-5f95-b60e-3ebb9f401bdb""}"
2013-06-03,"{""abstract"": ""The drug, lambrolizumab, significantly shrank melanoma tumors, the company reported on Sunday."", ""web_url"": ""https://www.nytimes.com/2013/06/03/business/merck-has-strong-results-in-a-cancer-drug-trial.html"", ""snippet"": ""The drug, lambrolizumab, significantly shrank melanoma tumors, the company reported on Sunday."", ""lead_paragraph"": ""CHICAGO \u2014 An experimental drug from Merck that unleashes the body\u2019s immune system significantly shrank tumors in 38 percent of patients with advanced melanoma, putting the company squarely in the race to bring to market one of what many experts view as the most promising class of drugs in years. "", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/06/03/business/merck/merck-articleLarge.jpg"", ""height"": 834, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/06/03/business/merck/merck-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 834}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/06/03/business/merck/merck-jumbo.jpg"", ""height"": 1024, ""width"": 737, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/06/03/business/merck/merck-superJumbo.jpg"", ""height"": 1041, ""width"": 749, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Merck Has Solid Results in a Cancer Drug Trial"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Has Solid Results In a Cancer Drug Trial"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Melanomas"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMERICAN SOCIETY OF CLINICAL ONCOLOGY"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2013-06-03T00:50:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8b8635db-c085-5eba-9dfd-1ea97855b5fd"", ""word_count"": 487, ""uri"": ""nyt://article/8b8635db-c085-5eba-9dfd-1ea97855b5fd""}"
2013-06-04,"{""abstract"": ""The drugs work by unleashing the immune system to attack cancer cells, much as it attacks bacteria or other foreign invaders in the human body."", ""web_url"": ""https://www.nytimes.com/2013/06/04/health/promising-new-cancer-drugs-empower-the-bodys-own-defense-system.html"", ""snippet"": ""The drugs work by unleashing the immune system to attack cancer cells, much as it attacks bacteria or other foreign invaders in the human body."", ""lead_paragraph"": ""CHICAGO \u2014 The early success of a new class of cancer drugs, revealed in test results released here over the last several days, has raised hope among the world\u2019s top cancer specialists that they may be on the verge of an important milestone in the fight against the disease."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/06/04/business/0604CANCER/0604CANCER-articleLarge.jpg"", ""height"": 397, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/06/04/business/0604CANCER/0604CANCER-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 397}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/06/04/business/0604CANCER/0604CANCER-jumbo.jpg"", ""height"": 678, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/06/04/business/0604CANCER/0604CANCER-superJumbo.jpg"", ""height"": 1355, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/06/04/business/0604CANCER/0604CANCER-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/06/04/business/0604CANCER/0604CANCER-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/06/04/business/0604CANCER/0604CANCER-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Promising New Cancer Drugs Empower the Body\u2019s Own Defense System"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Promising New Cancer Drugs Empower the Body\u2019s Own Defense System"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Immune System"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Melanomas"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2013-06-04T00:47:06+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2c83f60b-a940-5833-8622-8fc8f7cccf8d"", ""word_count"": 1228, ""uri"": ""nyt://article/2c83f60b-a940-5833-8622-8fc8f7cccf8d""}"
2013-07-01,"{""abstract"": ""Merck said the Food and Drug Administration had rejected an application for a new sleeping pill called suvorexant, but would probably approve it in smaller doses."", ""web_url"": ""https://www.nytimes.com/2013/07/02/business/fda-prefers-smaller-dosage-of-merck-sleep-drug.html"", ""snippet"": ""Merck said the Food and Drug Administration had rejected an application for a new sleeping pill called suvorexant, but would probably approve it in smaller doses."", ""lead_paragraph"": ""The Food and Drug Administration has rejected an application by Merck to sell a new sleeping pill, but indicated that it would probably approve the drug in lower doses."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""F.D.A. Prefers Smaller Dosage of Merck Sleep Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sleep"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2013-07-01T18:12:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b039a449-57f1-5171-af3f-68c919668c99"", ""word_count"": 313, ""uri"": ""nyt://article/b039a449-57f1-5171-af3f-68c919668c99""}"
2013-07-16,"{""abstract"": ""Rising Chinese demand for drugs is a boon for foreign companies, but bribery allegations against GlaxoSmithKline underscore the risk of scrutiny from officials."", ""web_url"": ""https://www.nytimes.com/2013/07/17/business/global/for-drug-makers-china-becomes-a-perilous-market.html"", ""snippet"": ""Rising Chinese demand for drugs is a boon for foreign companies, but bribery allegations against GlaxoSmithKline underscore the risk of scrutiny from officials."", ""lead_paragraph"": ""Multinational drug companies now employ more sales agents in China than they do in the United States, their largest market. Several, including Merck and GlaxoSmithKline, are making huge scientific investments in the country, including building research and development centers. Within the next few years, China is poised to surpass Japan as the world\u2019s second-largest pharmaceutical market."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/07/17/business/Drug-span/Drug-1374016413062-articleLarge.jpg"", ""height"": 322, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/07/17/business/Drug-span/Drug-1374016413062-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 322}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/07/17/business/Drug-span/Drug-1374016413062-jumbo.jpg"", ""height"": 549, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/07/17/business/Drug-span/Drug-1374016413062-superJumbo.jpg"", ""height"": 1098, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/07/17/business/Drug-span/Drug-1374016413062-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/07/17/business/Drug-span/Drug-1374016413062-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/07/17/business/Drug-span/Drug-1374016413062-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""For Global Drug Manufacturers, China Becomes a Perilous Market"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""For Global Drug Manufacturers, China Becomes a Perilous Market"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""China"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2013-07-16T16:30:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Global Business"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f25259ea-86fa-52ea-af59-da04b9780e2c"", ""word_count"": 1221, ""uri"": ""nyt://article/f25259ea-86fa-52ea-af59-da04b9780e2c""}"
2013-07-26,"{""abstract"": ""The European Medicines Agency said that there was little evidence that drugs to treat Type 2 diabetes could cause pancreatic inflammation or cancer."", ""web_url"": ""https://www.nytimes.com/2013/07/27/business/european-regulator-finds-little-risk-in-diabetes-drugs.html"", ""snippet"": ""The European Medicines Agency said that there was little evidence that drugs to treat Type 2 diabetes could cause pancreatic inflammation or cancer."", ""lead_paragraph"": ""Regulators in Europe have concluded that there is little evidence that widely used drugs to treat Type 2 diabetes could cause pancreatic inflammation or pancreatic cancer, a finding that might reassure patients while also removing a potential sales threat for Merck and some other drug companies."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""European Regulator Finds Little Risk in Diabetes Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""European Regulator Finds Little Risk in Diabetes Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Europe"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Regulation and Deregulation of Industry"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Diabetes"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Pancreatic Cancer"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""European Medicines Agency"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2013-07-26T12:50:29+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/46e05be3-fc83-5ed7-bc2f-ab7757dd3312"", ""word_count"": 524, ""uri"": ""nyt://article/46e05be3-fc83-5ed7-bc2f-ab7757dd3312""}"
2013-08-14,"{""abstract"": ""The Food and Drug Administration is considering the residual drowsiness that can persist the day after taking prescription sleep aids, and whether users can drive safely upon waking."", ""web_url"": ""https://www.nytimes.com/2013/08/14/business/to-judge-sleep-aids-us-looks-at-drowsy-driving-in-the-morning.html"", ""snippet"": ""The Food and Drug Administration is considering the residual drowsiness that can persist the day after taking prescription sleep aids, and whether users can drive safely upon waking."", ""lead_paragraph"": ""The first test for a new sleep drug is \u2014 unsurprisingly \u2014 how safely it puts people to sleep. Now comes a second test: how safely it lets people wake up."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/08/14/business/Driving/Driving-articleLarge.jpg"", ""height"": 337, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/08/14/business/Driving/Driving-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 337}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/08/14/business/Driving/Driving-jumbo.jpg"", ""height"": 575, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/08/14/business/Driving/Driving-superJumbo.jpg"", ""height"": 1150, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/08/14/business/Driving/Driving-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/08/14/business/Driving/Driving-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/08/14/business/Driving/Driving-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""To Judge Sleep Aids, U.S. Looks at Drowsy Driving in the Morning"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""To Judge Sleep Aids, U.S. Looks at Drowsy Driving in the Morning"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Driver Distraction and Fatigue"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sleep"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Traffic Accidents and Safety"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2013-08-14T01:20:40+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2388a804-246b-554c-926c-f663fdc25d89"", ""word_count"": 1158, ""uri"": ""nyt://article/2388a804-246b-554c-926c-f663fdc25d89""}"
2013-10-01,"{""abstract"": ""The company also announced that it was abandoning plans to move from Whitehouse Station, N.J., to a new headquarters and would cut $2.5 billion in costs in the next two years."", ""web_url"": ""https://www.nytimes.com/2013/10/02/business/merck-plans-to-lay-off-8500-workers.html"", ""snippet"": ""The company also announced that it was abandoning plans to move from Whitehouse Station, N.J., to a new headquarters and would cut $2.5 billion in costs in the next two years."", ""lead_paragraph"": ""The pharmaceutical company Merck announced on Tuesday that it would lay off 8,500 employees, cut $2.5 billion in costs over the next two years and undertake a restructuring of its troubled research and development unit, which has suffered several major setbacks in recent years."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Plans to Lay Off Another 8,500 Workers"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Plans to Lay Off Another 8,500 Workers"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Layoffs and Job Reductions"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Relocation of Business"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""New Jersey"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2013-10-01T15:52:06+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/07332ad1-44f6-5bc5-bf8b-43acf9979be9"", ""word_count"": 511, ""uri"": ""nyt://article/07332ad1-44f6-5bc5-bf8b-43acf9979be9""}"
2013-11-15,"{""abstract"": ""A promising new class of cholesterol-lowering drugs known as PCSK9 inhibitors is being developed."", ""web_url"": ""https://www.nytimes.com/2013/11/15/business/questions-for-a-new-class-of-cholesterol-drugs.html"", ""snippet"": ""A promising new class of cholesterol-lowering drugs known as PCSK9 inhibitors is being developed."", ""lead_paragraph"": ""New guidelines governing the use of cholesterol-lowering medicines are a huge change for doctors and a vast number of patients, but the impact on the drug industry is expected to be less tumultuous."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/11/15/business/SubPharma/SubPharma-articleLarge.jpg"", ""height"": 410, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/11/15/business/SubPharma/SubPharma-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 410}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/11/15/business/SubPharma/SubPharma-jumbo.jpg"", ""height"": 700, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/11/15/business/SubPharma/SubPharma-superJumbo.jpg"", ""height"": 1324, ""width"": 1938, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/11/15/business/SubPharma/SubPharma-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/11/15/business/SubPharma/SubPharma-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/11/15/business/SubPharma/SubPharma-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Questions for a New Class of Cholesterol Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Questions for a New Class of Cholesterol Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Statins (Cholesterol-Lowering Drugs)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Regeneron Pharmaceuticals Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Crestor (Drug)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vytorin (Drug)"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zetia (Drug)"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 11, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 12, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Heart"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2013-11-15T02:50:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/93a3433d-9389-5cb5-b440-c539fe1535a9"", ""word_count"": 862, ""uri"": ""nyt://article/93a3433d-9389-5cb5-b440-c539fe1535a9""}"
2013-12-05,"{""abstract"": ""Merck said that the purchase of AZ Electronic Materials, which makes chemicals used in semiconductors, would give it \u201cadditional growth areas in the electronics industry.\u201d"", ""web_url"": ""https://dealbook.nytimes.com/2013/12/05/merck-to-buy-specialty-chemical-company-for-2-57-billion/"", ""snippet"": ""Merck said that the purchase of AZ Electronic Materials, which makes chemicals used in semiconductors, would give it \u201cadditional growth areas in the electronics industry.\u201d"", ""lead_paragraph"": ""LONDON \u2014 The German drug and chemical maker Merck has made an all-cash offer to buy AZ Electronic Materials, a specialty chemical manufacturer, for 1.57 billion pounds, or about $2.57 billion, the companies said on Thursday."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/12/06/business/dbpix-merck2/dbpix-merck2-articleLarge.jpg"", ""height"": 403, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/12/06/business/dbpix-merck2/dbpix-merck2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 403}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/12/06/business/dbpix-merck2/dbpix-merck2-jumbo.jpg"", ""height"": 688, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/12/06/business/dbpix-merck2/dbpix-merck2-superJumbo.jpg"", ""height"": 1343, ""width"": 2000, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/12/06/business/dbpix-merck2/dbpix-merck2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/12/06/business/dbpix-merck2/dbpix-merck2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/12/06/business/dbpix-merck2/dbpix-merck2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck to Buy Specialty Chemical Company for $2.57 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Chemicals"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AZ Electronic Materials"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2013-12-05T12:46:54+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4a2de6d3-42c7-56db-958b-c47cfdf97ce0"", ""word_count"": 253, ""uri"": ""nyt://article/4a2de6d3-42c7-56db-958b-c47cfdf97ce0""}"
2013-12-06,"{""abstract"": ""Two companies are asking the Food and Drug Administration for approval to market tablets or liquids to treat allergies, drugs which are already available in Europe."", ""web_url"": ""https://www.nytimes.com/2013/12/06/business/treating-allergies-with-pills-or-drops-instead-of-shots.html"", ""snippet"": ""Two companies are asking the Food and Drug Administration for approval to market tablets or liquids to treat allergies, drugs which are already available in Europe."", ""lead_paragraph"": ""For much of her adult life, Shirley Hickey received two injections a week in an effort to tame severe allergies that caused frequent sore throats and sinus infections. Now she uses a less painful method."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/12/06/business/ALLERGY/ALLERGY-articleLarge.jpg"", ""height"": 375, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/12/06/business/ALLERGY/ALLERGY-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 375}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/12/06/business/ALLERGY/ALLERGY-jumbo.jpg"", ""height"": 640, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/12/06/business/ALLERGY/ALLERGY-superJumbo.jpg"", ""height"": 1281, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/12/06/business/ALLERGY/ALLERGY-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/12/06/business/ALLERGY/ALLERGY-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/12/06/business/ALLERGY/ALLERGY-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Treating Allergies With Pills or Drops Instead of Shots"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Treating Allergies With Pills or Drops Instead of Shots"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ALLERGIES"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Stallergenes SA"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2013-12-06T00:25:01+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8d1dbf6b-fa39-57ef-9524-59aa12fa778f"", ""word_count"": 1391, ""uri"": ""nyt://article/8d1dbf6b-fa39-57ef-9524-59aa12fa778f""}"
2013-12-31,"{""abstract"": ""Questions about Zilmax, a feed additive made by Merck, show the market dangers of an increasingly complicated global food chain, Kevin Allison of Reuters Breakingviews writes."", ""web_url"": ""https://dealbook.nytimes.com/2013/12/31/the-risks-of-investing-in-animal-medicine/"", ""snippet"": ""Questions about Zilmax, a feed additive made by Merck, show the market dangers of an increasingly complicated global food chain, Kevin Allison of Reuters Breakingviews writes."", ""lead_paragraph"": ""Animal medicine, whether for livestock or pets, is a booming business. Pfizer\u2019s recent spinoff, Zoetis, trades at a large valuation premium to traditional drug makers, for example."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""The Risks of Investing in Animal Medicine"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Cargill Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Tyson Foods Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Zoetis Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2013-12-31T17:00:27+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Kevin Allison"", ""person"": [{""firstname"": ""Kevin"", ""middlename"": null, ""lastname"": ""Allison"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/97a577bf-5552-53fc-bdd3-c10bb8e3e0a4"", ""word_count"": 403, ""uri"": ""nyt://article/97a577bf-5552-53fc-bdd3-c10bb8e3e0a4""}"
2014-03-27,"{""abstract"": ""In the wake of Baxter\u2019s split, Merck, Bayer and Johnson & Johnson may find it hard not to jump on the bandwagon, says Robert Cyran of Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/03/27/conscious-uncoupling-for-drug-makers/"", ""snippet"": ""In the wake of Baxter\u2019s split, Merck, Bayer and Johnson & Johnson may find it hard not to jump on the bandwagon, says Robert Cyran of Reuters Breakingviews."", ""lead_paragraph"": ""Baxter International has put conscious uncoupling on pharma\u2019s radar."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/28/business/dbpix-baxter2/dbpix-baxter2-jumbo.jpg"", ""height"": 374, ""width"": 523, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/28/business/dbpix-baxter2/dbpix-baxter2-superJumbo.jpg"", ""height"": 374, ""width"": 523, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/28/business/dbpix-baxter2/dbpix-baxter2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/03/28/business/dbpix-baxter2/dbpix-baxter2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/28/business/dbpix-baxter2/dbpix-baxter2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Conscious Uncoupling for Drug Makers"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Biotechnology"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baxter International"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-03-27T18:42:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/dffcc012-2fc0-597c-8c34-95bbdf1e8405"", ""word_count"": 354, ""uri"": ""nyt://article/dffcc012-2fc0-597c-8c34-95bbdf1e8405""}"
2014-05-01,"{""abstract"": ""The big health care company, is close to a deal to sell its consumer unit to Bayer for about $14 billion, a person briefed on the matter said on Thursday."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/01/bayer-nears-deal-for-merck-consumer-unit/"", ""snippet"": ""The big health care company, is close to a deal to sell its consumer unit to Bayer for about $14 billion, a person briefed on the matter said on Thursday."", ""lead_paragraph"": ""Updated, 8:01 p.m. | Merck, the big health care company, is close to a deal to sell its consumer unit to Bayer for about $14 billion, a person briefed on the matter said on Thursday."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""height"": 663, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 663}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-jumbo.jpg"", ""height"": 1024, ""width"": 927, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-superJumbo.jpg"", ""height"": 1760, ""width"": 1592, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck Said to Be Near Closing Deal With Bayer"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Merck Said To Be Near Closing Deal With Bayer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bayer AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-05-01T22:39:26+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/323dfe19-da70-578a-ad29-aeada6e33acb"", ""word_count"": 393, ""uri"": ""nyt://article/323dfe19-da70-578a-ad29-aeada6e33acb""}"
2014-05-06,"[{""abstract"": ""The German drug maker agreed to acquire Merck\u2019s consumer care business for $14.2 billion, gaining control of Claritin, Coppertone and Dr. Scholl\u2019s."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/06/bayer-to-buy-mercks-consumer-care-business-for-14-2-billion/"", ""snippet"": ""The German drug maker agreed to acquire Merck\u2019s consumer care business for $14.2 billion, gaining control of Claritin, Coppertone and Dr. Scholl\u2019s."", ""lead_paragraph"": ""Updated, 12:06 p.m. | LONDON \u2014 The German drug maker Bayer said on Tuesday that it had agreed to acquire Merck\u2019s consumer care business for $14.2 billion, a deal that will make Bayer one of the largest providers of over-the-counter products."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Bayer Deal to Expand Consumer Business With Merck Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Bayer Deal to Expand Consumer Business"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Dekkers, Marijn E"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bayer AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-06T10:43:04+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray and Katie Thomas"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/267536e1-6711-52b7-ab71-ec58b69cafad"", ""word_count"": 709, ""uri"": ""nyt://article/267536e1-6711-52b7-ab71-ec58b69cafad""}, {""abstract"": ""Bayer\u2019s $14.2 billion acquisition of Merck\u2019s consumer care business makes strategic sense and sizable tax breaks will help, writes Olaf Storbeck of Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/06/how-bayers-buy-makes-sense/"", ""snippet"": ""Bayer\u2019s $14.2 billion acquisition of Merck\u2019s consumer care business makes strategic sense and sizable tax breaks will help, writes Olaf Storbeck of Reuters Breakingviews."", ""lead_paragraph"": ""Bayer\u2019s $14.2 billion acquisition of Merck\u2019s consumer care business is less pricey than it looks."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-articleLarge.jpg"", ""height"": 365, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 365}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-jumbo.jpg"", ""height"": 622, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-superJumbo.jpg"", ""height"": 1244, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""How Bayer\u2019s Buy Makes Sense"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Credits, Deductions and Exemptions"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bayer AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-06T20:10:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Olaf Storbeck"", ""person"": [{""firstname"": ""Olaf"", ""middlename"": null, ""lastname"": ""Storbeck"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ace912f3-f982-51bf-826d-67f3073c7b64"", ""word_count"": 364, ""uri"": ""nyt://article/ace912f3-f982-51bf-826d-67f3073c7b64""}]"
2014-06-09,"{""abstract"": ""Merck will pay $24.50 a share in cash, or about $3.85 billion, for the biotechnology company Idenix in an effort to bolster its arsenal of potential drugs in the hotly competitive hepatitis C area."", ""web_url"": ""https://dealbook.nytimes.com/2014/06/09/merck-to-acquire-idenix-pharmaceuticals/"", ""snippet"": ""Merck will pay $24.50 a share in cash, or about $3.85 billion, for the biotechnology company Idenix in an effort to bolster its arsenal of potential drugs in the hotly competitive hepatitis C area."", ""lead_paragraph"": ""Updated, 8:32 p.m. | Merck will buy the biotechnology company Idenix Pharmaceuticals for $3.85 billion in an effort to bolster its arsenal of potential drugs in the competitive arena of hepatitis C treatments, the companies announced on Monday."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/10/business/Merck/Merck-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/06/10/business/Merck/Merck-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/10/business/Merck/Merck-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/10/business/Merck/Merck-superJumbo.jpg"", ""height"": 853, ""width"": 1280, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/10/business/Merck/Merck-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/06/10/business/Merck/Merck-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/10/business/Merck/Merck-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck Bids $3.8 Billion for an Edge in Hepatitis"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Merck Bids $3.8 Billion for an Edge in Hepatitis"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sovaldi (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Idenix Pharmaceuticals Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-06-09T11:42:40+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4ac748bf-67e9-5ea0-8ee7-c1df0b20c885"", ""word_count"": 869, ""uri"": ""nyt://article/4ac748bf-67e9-5ea0-8ee7-c1df0b20c885""}"
2014-09-04,"{""abstract"": ""The treatment unleashes the body\u2019s immune system against tumors, and will initially be used against advanced melanoma."", ""web_url"": ""https://www.nytimes.com/2014/09/05/business/merck-wins-approval-of-novel-immune-system-drug-for-cancer.html"", ""snippet"": ""The treatment unleashes the body\u2019s immune system against tumors, and will initially be used against advanced melanoma."", ""lead_paragraph"": ""The Food and Drug Administration on Thursday approved the first of an eagerly awaited new class of cancer drugs that unleashes the body\u2019s immune system to fight tumors."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/05/business/Drug/Drug-articleLarge.jpg"", ""height"": 567, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/09/05/business/Drug/Drug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 567}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/05/business/Drug/Drug-jumbo.jpg"", ""height"": 967, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/05/business/Drug/Drug-superJumbo.jpg"", ""height"": 1305, ""width"": 1382, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/05/business/Drug/Drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/09/05/business/Drug/Drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/05/business/Drug/Drug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""F.D.A. Allows First Use of a Novel Cancer Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Allows First Use of a Novel Cancer Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Immune System"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Melanomas"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-09-04T20:40:23+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/94af2b85-6573-5807-8017-f4f8f6a8f6d3"", ""word_count"": 1074, ""uri"": ""nyt://article/94af2b85-6573-5807-8017-f4f8f6a8f6d3""}"
2014-09-22,"[{""abstract"": ""The deal is expected to increase Merck\u2019s presence in North America and give it added exposure to markets in Asia. It represents a 37 percent premium to Sigma-Aldrich\u2019s closing price on Friday."", ""web_url"": ""https://dealbook.nytimes.com/2014/09/22/merck-of-germany-to-acquire-sigma-aldrich-for-17-billion/"", ""snippet"": ""The deal is expected to increase Merck\u2019s presence in North America and give it added exposure to markets in Asia. It represents a 37 percent premium to Sigma-Aldrich\u2019s closing price on Friday."", ""lead_paragraph"": ""LONDON \u2013\u00a0Merck\u00a0of Germany said on Monday that it had agreed to acquire the life sciences company\u00a0Sigma-Aldrich\u00a0for $17 billion."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/22/business/dealbook/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/09/22/business/dealbook/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/22/business/dealbook/dbpix-merck/dbpix-merck-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/22/business/dealbook/dbpix-merck/dbpix-merck-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/22/business/dealbook/dbpix-merck/dbpix-merck-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/09/22/business/dealbook/dbpix-merck/dbpix-merck-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/22/business/dealbook/dbpix-merck/dbpix-merck-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck of Germany to Acquire Sigma-Aldrich for $17 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck of Germany"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sigma-Aldrich Corporation"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2014-09-22T10:31:52+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ae850cd5-fccb-5442-854b-6de14046599e"", ""word_count"": 292, ""uri"": ""nyt://article/ae850cd5-fccb-5442-854b-6de14046599e""}, {""abstract"": ""A rare bright spot in the European economy in recent years, many of the biggest German companies have begun capitalizing on their strength, striking big deals for overseas competitors."", ""web_url"": ""https://dealbook.nytimes.com/2014/09/22/german-companies-continue-their-buying-spree/"", ""snippet"": ""A rare bright spot in the European economy in recent years, many of the biggest German companies have begun capitalizing on their strength, striking big deals for overseas competitors."", ""lead_paragraph"": ""Germany\u2019s businesses have been the rare bright spot in the European economy in recent years, generating jobs and profits even as neighboring countries face persistent unemployment."", ""print_section"": ""B"", ""print_page"": ""9"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/23/business/LIFE/LIFE-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/09/23/business/LIFE/LIFE-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/23/business/LIFE/LIFE-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/23/business/LIFE/LIFE-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/23/business/LIFE/LIFE-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/09/23/business/LIFE/LIFE-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/23/business/LIFE/LIFE-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Cash-Stuffed German Companies on a Global Buying Spree"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Cash-Stuffed German Companies on a Global Buying Spree"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Economic Conditions and Trends"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Dresser-Rand Group Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck of Germany"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Siemens AG"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sigma-Aldrich Corporation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Germany"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-09-22T16:18:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c31184af-f19c-54d3-b9f9-6c80281b4798"", ""word_count"": 1086, ""uri"": ""nyt://article/c31184af-f19c-54d3-b9f9-6c80281b4798""}]"
2014-10-27,"{""abstract"": ""The pharmaceutical company\u2019s earnings beat expectations, however, helped by sales of the diabetes drug Januvia and revenue in emerging markets."", ""web_url"": ""https://www.nytimes.com/2014/10/28/business/merck-reports-third-quarter-earnings.html"", ""snippet"": ""The pharmaceutical company\u2019s earnings beat expectations, however, helped by sales of the diabetes drug Januvia and revenue in emerging markets."", ""lead_paragraph"": ""The drug maker Merck said revenue dropped by 4 percent in the third quarter as sales of its vaccine for cervical cancer fell and other drugs encountered increased competition from generics. Still, the company\u2019s earnings, reported Monday, beat analysts\u2019 expectations."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Sales Down 4%; Profit Beats Forecasts "", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Sales Down 4%; Profit Beats Forecasts"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-10-27T16:00:41+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/aca69630-3b91-56e0-922b-386fd23eac82"", ""word_count"": 445, ""uri"": ""nyt://article/aca69630-3b91-56e0-922b-386fd23eac82""}"
2014-11-17,"{""abstract"": ""The alliance between the American and German companies is expected to strengthen Merck\u2019s oncology business in several important markets, including the United States."", ""web_url"": ""https://dealbook.nytimes.com/2014/11/17/pfizer-to-pay-up-to-2-9-billion-in-cancer-drug-deal-with-merck-of-germany/"", ""snippet"": ""The alliance between the American and German companies is expected to strengthen Merck\u2019s oncology business in several important markets, including the United States."", ""lead_paragraph"": ""LONDON \u2014 Merck of Germany said on Monday that the American drug giant Pfizer had agreed to pay $850 million upfront and as much as $2 billion later in a deal to jointly develop one of Merck\u2019s cancer drugs."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer to Pay up to $2.9 Billion in Cancer Drug Deal With Merck of Germany"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck of Germany"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Germany"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-11-17T10:32:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/33223746-b95c-55ec-8365-355da0986132"", ""word_count"": 415, ""uri"": ""nyt://article/33223746-b95c-55ec-8365-355da0986132""}"
2014-12-06,"{""abstract"": ""The deal would represent another multibillion-dollar health care transaction in a banner year for mergers and acquisitions in the industry."", ""web_url"": ""https://dealbook.nytimes.com/2014/12/05/merck-in-talks-to-acquire-drug-maker-cubist-for-more-than-7-billion/"", ""snippet"": ""The deal would represent another multibillion-dollar health care transaction in a banner year for mergers and acquisitions in the industry."", ""lead_paragraph"": ""Merck & Company, the big drug maker, is in talks to acquire the biopharmaceuticals company Cubist for more than $7 billion, according to people briefed on the matter."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck Said to Weigh Acquisition of Rival Drug Maker Cubist"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Merck Said to Weigh Acquisition of a Rival"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-12-06T00:01:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/62795514-c399-53d1-a39e-3c17aef1e82f"", ""word_count"": 724, ""uri"": ""nyt://article/62795514-c399-53d1-a39e-3c17aef1e82f""}"
2014-12-07,"{""abstract"": ""In two early stage studies, Bristol-Myers Squibb\u2019s nivolumab and Merck\u2019s pembrolizumab shrank tumors in patients with Hodgkin\u2019s lymphoma."", ""web_url"": ""https://www.nytimes.com/2014/12/07/business/cancer-drugs-that-free-brake-on-immune-system-show-promise-for-hodgkins.html"", ""snippet"": ""In two early stage studies, Bristol-Myers Squibb\u2019s nivolumab and Merck\u2019s pembrolizumab shrank tumors in patients with Hodgkin\u2019s lymphoma."", ""lead_paragraph"": ""Drugs that free the body\u2019s immune system to fight cancer have shown strong preliminary results in treating Hodgkin\u2019s lymphoma, shrinking tumors in well over half of patients who had exhausted many other treatment options, researchers reported on Saturday."", ""print_section"": ""A"", ""print_page"": ""30"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Cancer Drugs That Free Brake on Immune System Show Promise for Hodgkin\u2019s"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Cancer Drugs That Free Brake on Immune System Show Promise for Hodgkin\u2019s"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""New England Journal of Medicine"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hodgkin's Lymphoma"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-12-07T00:41:38+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/752a15eb-b75e-5860-b9cc-88591ffbbd6e"", ""word_count"": 606, ""uri"": ""nyt://article/752a15eb-b75e-5860-b9cc-88591ffbbd6e""}"
2014-12-08,"[{""abstract"": ""The deal will give Merck, the second-largest American drug maker after Pfizer, control of the largest antibiotics company, and deepen its ties with hospitals."", ""web_url"": ""https://dealbook.nytimes.com/2014/12/08/merck-agrees-to-acquire-drug-maker-cubist-for-9-5-billion/"", ""snippet"": ""The deal will give Merck, the second-largest American drug maker after Pfizer, control of the largest antibiotics company, and deepen its ties with hospitals."", ""lead_paragraph"": ""Deal making in the health care industry has been booming all year, with medical technology companies and cosmetic drug makers changing hands at rich premiums."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/12/09/business/Drug/Drug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/12/09/business/Drug/Drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck in $8.4 Billion Deal for Cubist, Big Maker of Antibiotics"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Merck in Deal for Big Maker of Antibiotics"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Biotechnology and Bioengineering"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cubist Pharmaceuticals Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-12-08T12:53:59+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d7ab937e-c988-5d8e-a3ba-2a9d72be2698"", ""word_count"": 970, ""uri"": ""nyt://article/d7ab937e-c988-5d8e-a3ba-2a9d72be2698""}, {""abstract"": ""Merck agrees to buy Cubist in a deal valued at $9.5 billion. | A hedge fund keeps an S.E.C. inquiry quiet. | Big deals are back this year. | Deal makers regain their power on Wall Street."", ""web_url"": ""https://dealbook.nytimes.com/2014/12/08/morning-agenda-merck-goes-after-cubist/"", ""snippet"": ""Merck agrees to buy Cubist in a deal valued at $9.5 billion. | A hedge fund keeps an S.E.C. inquiry quiet. | Big deals are back this year. | Deal makers regain their power on Wall Street."", ""lead_paragraph"": ""The big drug maker Merck & Company announced on Monday that it had agreed to buy Cubist Pharmaceuticals for $9.5 billion, including debt, Merck said in a statement. Under the terms of the agreement, Merck will acquire Cubist for $102 a share in cash, or 35 percent above Cubist\u2019s average stock price over the last five trading days, Merck said."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Morning Agenda: Merck Goes After Cubist"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-12-08T13:17:56+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c08b8cc1-6557-5ed8-8f51-e4be3839db61"", ""word_count"": 2239, ""uri"": ""nyt://article/c08b8cc1-6557-5ed8-8f51-e4be3839db61""}, {""abstract"": ""Merck is paying only about 4.3 times Cubist\u2019s estimated revenue for next year \u2014 about the same multiple investors give Merck itself, making the acquisition look like a relative bargain, writes Robert Cyran of Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/12/08/revival-for-antibiotics-could-spur-deals/"", ""snippet"": ""Merck is paying only about 4.3 times Cubist\u2019s estimated revenue for next year \u2014 about the same multiple investors give Merck itself, making the acquisition look like a relative bargain, writes Robert Cyran of Reuters Breakingviews."", ""lead_paragraph"": ""Superbugs may have beneficial side effects \u2013 for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck is betting $8.4 billion that the antibiotics used to fight them will become more profitable."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Revival for Antibiotics Could Spur Deals"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""ANTIBIOTICS"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cubist Pharmaceuticals Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-12-08T19:39:29+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/31c7ecfb-55f6-5a0e-920a-74533c0228df"", ""word_count"": 378, ""uri"": ""nyt://article/31c7ecfb-55f6-5a0e-920a-74533c0228df""}]"
2014-12-09,"{""abstract"": ""Just hours after announcing its $8.4 billion acquisition of Cubist Pharmaceuticals, a Delaware judge invalidated patents owned by the antibiotics maker. Merck appears to have been caught up in the M.&.A. exuberance, says Robert Cyran of Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/12/09/mercks-rose-colored-deal-making/"", ""snippet"": ""Just hours after announcing its $8.4 billion acquisition of Cubist Pharmaceuticals, a Delaware judge invalidated patents owned by the antibiotics maker. Merck appears to have been caught up in the M.&.A. exuberance, says Robert Cyran of Reuters Br..."", ""lead_paragraph"": ""The M.&A. frenzy appears to have influenced Merck\u2019s risk assessment. Just hours after announcing its $8.4 billion acquisition of Cubist Pharmaceuticals on Monday, a judge invalidated patents owned by the antibiotics maker. Potential lost sales are reflected in the billions erased from Merck\u2019s market value."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck\u2019s Rose-Colored Glasses in Cubist Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""ANTIBIOTICS"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Inventions and Patents"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cubist Pharmaceuticals Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-12-09T19:30:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d5fe4dae-9f6a-5f97-ad57-f29e4c91ba68"", ""word_count"": 369, ""uri"": ""nyt://article/d5fe4dae-9f6a-5f97-ad57-f29e4c91ba68""}"
2014-12-11,"{""abstract"": ""The hospital said it would halt injections of a vaccine licensed to Merck until next month, after some test subjects reported mild joint pain."", ""web_url"": ""https://www.nytimes.com/2014/12/12/business/geneva-hospital-pauses-test-of-an-ebola-vaccine.html"", ""snippet"": ""The hospital said it would halt injections of a vaccine licensed to Merck until next month, after some test subjects reported mild joint pain."", ""lead_paragraph"": ""A test of an experimental Ebola vaccine recently licensed to Merck has been temporarily paused after some vaccinated volunteers experienced pain in their joints, a medical center in Geneva announced on Thursday."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/12/business/Vaccine/Vaccine-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/12/12/business/Vaccine/Vaccine-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/12/business/Vaccine/Vaccine-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/12/business/Vaccine/Vaccine-superJumbo.jpg"", ""height"": 1364, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/12/business/Vaccine/Vaccine-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/12/12/business/Vaccine/Vaccine-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/12/business/Vaccine/Vaccine-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Hospital Pauses Test of an Ebola Vaccine Licensed to Merck"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Hospital Pauses Test of an Ebola Vaccine Licensed to Merck"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Ebola Virus"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Geneva (Switzerland)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Public Health Agency of Canada"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""NewLink Genetics Corporation"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Health and Human Services Department"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2014-12-11T19:58:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7a830d01-c74d-5cda-bd82-f45ee3298a56"", ""word_count"": 760, ""uri"": ""nyt://article/7a830d01-c74d-5cda-bd82-f45ee3298a56""}"
2015-01-23,"{""abstract"": ""Tests of drugs developed by GlaxoSmithKline and Merck are expected to begin in Liberia in two weeks, federal officials said."", ""web_url"": ""https://www.nytimes.com/2015/01/23/business/international/trial-of-2-ebola-vaccines-effectiveness-is-announced.html"", ""snippet"": ""Tests of drugs developed by GlaxoSmithKline and Merck are expected to begin in Liberia in two weeks, federal officials said."", ""lead_paragraph"": ""Federal officials said on Thursday that the first clinical trial to test the effectiveness of Ebola vaccines was expected to begin in Liberia in two weeks."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Trial of 2 Ebola Vaccines\u2019 Effectiveness Is Announced"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Ebola Virus"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Liberia"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2015-01-23T05:00:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a8f04534-33b0-54c3-9972-7aaf86096eff"", ""word_count"": 272, ""uri"": ""nyt://article/a8f04534-33b0-54c3-9972-7aaf86096eff""}"
2015-03-04,"{""abstract"": ""Opdivo, from Bristol-Myers Squibb, which harnesses the body\u2019s own immune system to attack tumors, was approved after strong results in a study."", ""web_url"": ""https://www.nytimes.com/2015/03/05/business/lung-cancer-treatment-using-immune-system-wins-fda-approval.html"", ""snippet"": ""Opdivo, from Bristol-Myers Squibb, which harnesses the body\u2019s own immune system to attack tumors, was approved after strong results in a study."", ""lead_paragraph"": ""The first immune-based treatment for lung cancer won approval from the Food and Drug Administration on Wednesday, and it could displace more conventional chemotherapy for certain patients, at least."", ""print_section"": ""B"", ""print_page"": ""10"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Lung Cancer Treatment Using Immune System Wins F.D.A. Approval"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Backs a Lung Cancer Therapy"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Lung Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Melanomas"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-03-04T22:49:31+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e835a4d2-776a-5666-9b20-1c8850a5fb11"", ""word_count"": 627, ""uri"": ""nyt://article/e835a4d2-776a-5666-9b20-1c8850a5fb11""}"
2015-03-16,"{""abstract"": ""The higher offer quickly put an end to Endo\u2019s rival bid, but the added cost, along with the debt Valeant already holds, may hurt the company."", ""web_url"": ""https://www.nytimes.com/2015/03/17/business/dealbook/valeants-sweetened-bid-for-salix-may-have-delivered-2-knockouts.html"", ""snippet"": ""The higher offer quickly put an end to Endo\u2019s rival bid, but the added cost, along with the debt Valeant already holds, may hurt the company."", ""lead_paragraph"": ""The sweetened $11 billion bid by Valeant Pharmaceuticals for Salix Pharmaceuticals may have scored two knockouts. By coming up with an extra 9 percent over its previous offer, the acquisitive drug maker, now backed by the hedge fund executive William A. Ackman, quickly put an end to a rival bid from Endo International. But the extra cash required, and the debt already on its balance sheet, leave Valeant\u2019s business model looking wobbly."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-superJumbo.jpg"", ""height"": 1364, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Valeant\u2019s Sweetened Bid for Salix May Have Delivered 2 Knockouts"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Valeant Pharmaceuticals International Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Salix Pharmaceuticals Ltd"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Endo International PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Ackman, William A"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-03-16T21:45:43+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/38f246e6-9e8f-599a-8c48-69100ddea562"", ""word_count"": 387, ""uri"": ""nyt://article/38f246e6-9e8f-599a-8c48-69100ddea562""}"
2015-05-07,"{""abstract"": ""Johnson & Johnson named the bioethicist Arthur L. Caplan to create a panel to decide on patients\u2019 requests for lifesaving medicines before they are approved."", ""web_url"": ""https://www.nytimes.com/2015/05/07/business/company-creates-bioethics-panel-on-trial-drugs.html"", ""snippet"": ""Johnson & Johnson named the bioethicist Arthur L. Caplan to create a panel to decide on patients\u2019 requests for lifesaving medicines before they are approved."", ""lead_paragraph"": ""Johnson & Johnson has appointed a nationally known bioethicist to create a panel that will make decisions about patients\u2019 requests for potentially lifesaving medicine, responding to an emotional debate over whether companies should allow desperately ill people to have access to the drugs before they are approved."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/07/business/Ethics/Ethics-articleLarge.jpg"", ""height"": 936, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/05/07/business/Ethics/Ethics-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 936}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/07/business/Ethics/Ethics-jumbo.jpg"", ""height"": 984, ""width"": 631, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/07/business/Ethics/Ethics-superJumbo.jpg"", ""height"": 984, ""width"": 631, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/07/business/Ethics/Ethics-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/05/07/business/Ethics/Ethics-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/07/business/Ethics/Ethics-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Company Creates Bioethics Panel on Trial Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Company Creates Panel for Access to Trial Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Caplan, Arthur L"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""New York University Langone Medical Center"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Chimerix Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Ethics and Official Misconduct"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2015-05-07T04:01:15+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/33bf8157-acaf-5847-8be6-234e9850e1c6"", ""word_count"": 1614, ""uri"": ""nyt://article/33bf8157-acaf-5847-8be6-234e9850e1c6""}"
2015-05-29,"{""abstract"": ""A study sheds light on why the new medicines seem to work for some cancers and not others."", ""web_url"": ""https://www.nytimes.com/2015/05/30/business/new-class-of-drugs-shows-more-promise-in-treating-cancer.html"", ""snippet"": ""A study sheds light on why the new medicines seem to work for some cancers and not others."", ""lead_paragraph"": ""A new drug that unleashes the body\u2019s immune system to attack tumors can prolong the lives of people with the most common form of lung cancer, doctors reported on Friday, the latest example of the significant results being achieved by this new class of medicines."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/30/business/30lung-web/30lung-web-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/05/30/business/30lung-web/30lung-web-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/30/business/30lung-web/30lung-web-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/30/business/30lung-web/30lung-web-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/30/business/30lung-web/30lung-web-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/05/30/business/30lung-web/30lung-web-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/30/business/30lung-web/30lung-web-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""New Class of Drugs Shows More Promise in Treating Cancer"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""New Promise in New Class of Drugs for Cancer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lung Cancer"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""New England Journal of Medicine"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tumors"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Immune System"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Colon and Colorectal Cancer"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prostate Cancer"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMERICAN SOCIETY OF CLINICAL ONCOLOGY"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 12, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Skin Cancer"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2015-05-29T18:00:49+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/bf667393-fcb4-5b3c-ab99-781cfe3fa4da"", ""word_count"": 1109, ""uri"": ""nyt://article/bf667393-fcb4-5b3c-ab99-781cfe3fa4da""}"
2016-01-11,"{""abstract"": ""Some pharmaceutical companies will form the National Immunotherapy Coalition to rapidly test various combinations of promising new types of cancer drugs."", ""web_url"": ""https://www.nytimes.com/2016/01/12/business/drug-companies-to-try-a-unified-front-against-cancer.html"", ""snippet"": ""Some pharmaceutical companies will form the National Immunotherapy Coalition to rapidly test various combinations of promising new types of cancer drugs."", ""lead_paragraph"": ""SAN FRANCISCO \u2014 Some leading pharmaceutical companies are joining forces in an effort to speed the testing of new types of cancer drugs that harness the body\u2019s immune system to battle tumors."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-articleLarge.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 419}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-jumbo.jpg"", ""height"": 716, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-superJumbo.jpg"", ""height"": 1432, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Drug Companies to Try a Unified Front Against Cancer"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Soon-Shiong, Patrick"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Celgene Corporation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2016-01-11T15:46:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e37fcae4-ae54-52e9-923d-774b4b8ee48f"", ""word_count"": 505, ""uri"": ""nyt://article/e37fcae4-ae54-52e9-923d-774b4b8ee48f""}"
2016-08-05,"[{""abstract"": ""Bristol-Myers Squibb said the drug had not slowed the progression of advanced lung cancer in a test seeking approval to use it as an initial treatment."", ""web_url"": ""https://www.nytimes.com/2016/08/06/business/lung-cancer-drug-opdivo-fails-clinical-trial-to-expand-use.html"", ""snippet"": ""Bristol-Myers Squibb said the drug had not slowed the progression of advanced lung cancer in a test seeking approval to use it as an initial treatment."", ""lead_paragraph"": ""The hot new field of immunotherapy got a shock on Friday when a best-selling new drug failed as an initial treatment for lung cancer in a clinical trial."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/08/06/business/06DRUG/06DRUG-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-articleLarge.jpg"", ""height"": 401, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/08/06/business/06DRUG/06DRUG-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 401}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-jumbo.jpg"", ""height"": 684, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-superJumbo.jpg"", ""height"": 1369, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Immunotherapy Drug Opdivo Fails Clinical Trial to Expand Use"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Immunotherapy Drug Fails Lung Cancer Trial"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lung Cancer"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2016-08-05T15:59:16+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3b2b8277-ba3d-5c85-9bda-ba2124e1ee1c"", ""word_count"": 1045, ""uri"": ""nyt://article/3b2b8277-ba3d-5c85-9bda-ba2124e1ee1c""}, {""abstract"": ""Investors wiped off billions in value after Bristol\u2019s cancer drug trial failed. The stumble will allow its more cautious rival to clean up."", ""web_url"": ""https://www.nytimes.com/2016/08/06/business/dealbook/bristol-myers-squibbs-hubris-cost-it-21-billion.html"", ""snippet"": ""Investors wiped off billions in value after Bristol\u2019s cancer drug trial failed. The stumble will allow its more cautious rival to clean up."", ""lead_paragraph"": ""Bristol-Myers Squibb has suffered a $21 billion self-inflicted wound."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/08/06/business/06DRUG/06DRUG-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-articleLarge.jpg"", ""height"": 401, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/08/06/business/06DRUG/06DRUG-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 401}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-jumbo.jpg"", ""height"": 684, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-superJumbo.jpg"", ""height"": 1369, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Bristol-Myers Squibb\u2019s Hubris Cost It $21 Billion"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lung Cancer"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2016-08-05T18:03:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/22153e7e-a684-5867-a538-88f5fd60e091"", ""word_count"": 413, ""uri"": ""nyt://article/22153e7e-a684-5867-a538-88f5fd60e091""}]"
